Clustering O
of O
missense O
mutations O
in O
the O
ataxia B-disease
- I-disease
telangiectasia I-disease
gene O
in O
a O
sporadic B-disease
T I-disease
- I-disease
cell I-disease
leukaemia I-disease
. O

Ataxia B-disease
- I-disease
telangiectasia I-disease
( O
A B-disease
- I-disease
T I-disease
) O
is O
a O
recessive B-disease
multi I-disease
- I-disease
system I-disease
disorder I-disease
caused O
by O
mutations O
in O
the O
ATM O
gene O
at O
11q22 O
- O
q23 O
( O
ref O
. O
3 O
) O
. O

The O
risk O
of O
cancer B-disease
, O
especially O
lymphoid B-disease
neoplasias I-disease
, O
is O
substantially O
elevated O
in O
A B-disease
- I-disease
T I-disease
patients O
and O
has O
long O
been O
associated O
with O
chromosomal O
instability O
. O

By O
analysing O
tumour B-disease
DNA O
from O
patients O
with O
sporadic B-disease
T I-disease
- I-disease
cell I-disease
prolymphocytic I-disease
leukaemia I-disease
( O
T B-disease
- I-disease
PLL I-disease
) O
, O
a O
rare O
clonal B-disease
malignancy I-disease
with O
similarities O
to O
a O
mature B-disease
T I-disease
- I-disease
cell I-disease
leukaemia I-disease
seen O
in O
A B-disease
- I-disease
T I-disease
, O
we O
demonstrate O
a O
high O
frequency O
of O
ATM O
mutations O
in O
T B-disease
- I-disease
PLL I-disease
. O

In O
marked O
contrast O
to O
the O
ATM O
mutation O
pattern O
in O
A B-disease
- I-disease
T I-disease
, O
the O
most O
frequent O
nucleotide O
changes O
in O
this O
leukaemia B-disease
were O
missense O
mutations O
. O

These O
clustered O
in O
the O
region O
corresponding O
to O
the O
kinase O
domain O
, O
which O
is O
highly O
conserved O
in O
ATM O
- O
related O
proteins O
in O
mouse O
, O
yeast O
and O
Drosophila O
. O

The O
resulting O
amino O
- O
acid O
substitutions O
are O
predicted O
to O
interfere O
with O
ATP O
binding O
or O
substrate O
recognition O
. O

Two O
of O
seventeen O
mutated O
T B-disease
- I-disease
PLL I-disease
samples O
had O
a O
previously O
reported O
A B-disease
- I-disease
T I-disease
allele O
. O

In O
contrast O
, O
no O
mutations O
were O
detected O
in O
the O
p53 O
gene O
, O
suggesting O
that O
this O
tumour B-disease
suppressor O
is O
not O
frequently O
altered O
in O
this O
leukaemia B-disease
. O

Occasional O
missense O
mutations O
in O
ATM O
were O
also O
found O
in O
tumour B-disease
DNA O
from O
patients O
with O
B B-disease
- I-disease
cell I-disease
non I-disease
- I-disease
Hodgkins I-disease
lymphomas I-disease
( O
B B-disease
- I-disease
NHL I-disease
) O
and O
a O
B B-disease
- I-disease
NHL I-disease
cell O
line O
. O

The O
evidence O
of O
a O
significant O
proportion O
of O
loss O
- O
of O
- O
function O
mutations O
and O
a O
complete O
absence O
of O
the O
normal O
copy O
of O
ATM O
in O
the O
majority O
of O
mutated O
tumours B-disease
establishes O
somatic O
inactivation O
of O
this O
gene O
in O
the O
pathogenesis O
of O
sporadic B-disease
T I-disease
- I-disease
PLL I-disease
and O
suggests O
that O
ATM O
acts O
as O
a O
tumour B-disease
suppressor O
. O

As O
constitutional O
DNA O
was O
not O
available O
, O
a O
putative O
hereditary O
predisposition O
to O
T B-disease
- I-disease
PLL I-disease
will O
require O
further O
investigation O
. O
. O

Myotonic B-disease
dystrophy I-disease
protein O
kinase O
is O
involved O
in O
the O
modulation O
of O
the O
Ca2 O
+ O
homeostasis O
in O
skeletal O
muscle O
cells O
. O

Myotonic B-disease
dystrophy I-disease
( O
DM B-disease
) O
, O
the O
most O
prevalent O
muscular B-disease
disorder I-disease
in O
adults O
, O
is O
caused O
by O
( O
CTG O
) O
n O
- O
repeat O
expansion O
in O
a O
gene O
encoding O
a O
protein O
kinase O
( O
DM B-disease
protein O
kinase O
; O
DMPK O
) O
and O
involves O
changes O
in O
cytoarchitecture O
and O
ion O
homeostasis O
. O

To O
obtain O
clues O
to O
the O
normal O
biological O
role O
of O
DMPK O
in O
cellular O
ion O
homeostasis O
, O
we O
have O
compared O
the O
resting O
[ O
Ca2 O
+ O
] O
i O
, O
the O
amplitude O
and O
shape O
of O
depolarization O
- O
induced O
Ca2 O
+ O
transients O
, O
and O
the O
content O
of O
ATP O
- O
driven O
ion O
pumps O
in O
cultured O
skeletal O
muscle O
cells O
of O
wild O
- O
type O
and O
DMPK O
[ O
- O
/ O
- O
] O
knockout O
mice O
. O

In O
vitro O
- O
differentiated O
DMPK O
[ O
- O
/ O
- O
] O
myotubes O
exhibit O
a O
higher O
resting O
[ O
Ca2 O
+ O
] O
i O
than O
do O
wild O
- O
type O
myotubes O
because O
of O
an O
altered O
open O
probability O
of O
voltage O
- O
dependent O
l O
- O
type O
Ca2 O
+ O
and O
Na O
+ O
channels O
. O

The O
mutant O
myotubes O
exhibit O
smaller O
and O
slower O
Ca2 O
+ O
responses O
upon O
triggering O
by O
acetylcholine O
or O
high O
external O
K O
+ O
. O

In O
addition O
, O
we O
observed O
that O
these O
Ca2 O
+ O
transients O
partially O
result O
from O
an O
influx O
of O
extracellular O
Ca2 O
+ O
through O
the O
l O
- O
type O
Ca2 O
+ O
channel O
. O

Neither O
the O
content O
nor O
the O
activity O
of O
Na O
+ O
/ O
K O
+ O
ATPase O
and O
sarcoplasmic O
reticulum O
Ca2 O
+ O
- O
ATPase O
are O
affected O
by O
DMPK O
absence O
. O

In O
conclusion O
, O
our O
data O
suggest O
that O
DMPK O
is O
involved O
in O
modulating O
the O
initial O
events O
of O
excitation O
- O
contraction O
coupling O
in O
skeletal O
muscle O
. O
. O

Constitutional O
RB1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
unilateral B-disease
retinoblastoma I-disease
. O

In O
most O
patients O
with O
isolated O
unilateral B-disease
retinoblastoma I-disease
, O
tumor B-disease
development O
is O
initiated O
by O
somatic O
inactivation O
of O
both O
alleles O
of O
the O
RB1 O
gene O
. O

However O
, O
some O
of O
these O
patients O
can O
transmit O
retinoblastoma B-disease
predisposition O
to O
their O
offspring O
. O

To O
determine O
the O
frequency O
and O
nature O
of O
constitutional O
RB1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
unilateral B-disease
retinoblastoma I-disease
, O
we O
analyzed O
DNA O
from O
peripheral O
blood O
and O
from O
tumor B-disease
tissue O
. O

The O
analysis O
of O
tumors B-disease
from O
54 O
( O
71 O
% O
) O
of O
76 O
informative O
patients O
showed O
loss O
of O
constitutional O
heterozygosity O
( O
LOH O
) O
at O
intragenic O
loci O
. O

Three O
of O
13 O
uninformative O
patients O
had O
constitutional O
deletions O
. O

For O
39 O
randomly O
selected O
tumors B-disease
, O
SSCP O
, O
hetero O
- O
duplex O
analysis O
, O
sequencing O
, O
and O
Southern O
blot O
analysis O
were O
used O
to O
identify O
mutations O
. O

Mutations O
were O
detected O
in O
21 O
( O
91 O
% O
) O
of O
23 O
tumors B-disease
with O
LOH O
. O

In O
6 O
( O
38 O
% O
) O
of O
16 O
tumors B-disease
without O
LOH O
, O
one O
mutation O
was O
detected O
, O
and O
in O
9 O
( O
56 O
% O
) O
of O
the O
tumors B-disease
without O
LOH O
, O
both O
mutations O
were O
found O
. O

Thus O
, O
a O
total O
of O
45 O
mutations O
were O
identified O
in O
tumors B-disease
of O
36 O
patients O
. O

Thirty O
- O
nine O
of O
the O
mutations O
- O
including O
34 O
small O
mutations O
, O
2 O
large O
structural O
alterations O
, O
and O
hypermethylation O
in O
3 O
tumors O
- O
were O
not O
detected O
in O
the O
corresponding O
peripheral O
blood O
DNA O
. O

In O
6 O
( O
17 O
% O
) O
of O
the O
36 O
patients O
, O
a O
mutation O
was O
detected O
in O
constitutional O
DNA O
, O
and O
1 O
of O
these O
mutations O
is O
known O
to O
be O
associated O
with O
reduced O
expressivity O
. O

The O
presence O
of O
a O
constitutional O
mutation O
was O
not O
associated O
with O
an O
early O
age O
at O
treatment O
. O

In O
1 O
patient O
, O
somatic O
mosaicism O
was O
demonstrated O
by O
molecular O
analysis O
of O
DNA O
and O
RNA O
from O
peripheral O
blood O
. O

In O
2 O
patients O
without O
a O
detectable O
mutation O
in O
peripheral O
blood O
, O
mosaicism O
was O
suggested O
because O
1 O
of O
the O
patients O
showed O
multifocal O
tumors B-disease
and O
the O
other O
later O
developed O
bilateral B-disease
retinoblastoma I-disease
. O

In O
conclusion O
, O
our O
results O
emphasize O
that O
the O
manifestation O
and O
transmissibility O
of O
retinoblastoma B-disease
depend O
on O
the O
nature O
of O
the O
first O
mutation O
, O
its O
time O
in O
development O
, O
and O
the O
number O
and O
types O
of O
cells O
that O
are O
affected O
. O
. O

Hereditary B-disease
deficiency I-disease
of I-disease
the I-disease
fifth I-disease
component I-disease
of I-disease
complement I-disease
in O
man O
. O

I O
. O

Clinical O
, O
immunochemical O
, O
and O
family O
studies O
. O

The O
first O
recognized O
human O
kindred O
with O
hereditary B-disease
deficiency I-disease
of I-disease
the I-disease
fifth I-disease
component I-disease
of I-disease
complement I-disease
( O
C5 O
) O
is O
described O
. O

The O
proband O
, O
a O
20 O
- O
year O
- O
old O
black O
female O
with O
systemic B-disease
lupus I-disease
erythematosus I-disease
since O
age O
11 O
, O
lacked O
serum O
hemolytic O
complement O
activity O
, O
even O
during O
remission O
. O

C5 O
was O
undetectable O
in O
her O
serum O
by O
both O
immunodiffusion O
and O
hemolytic O
assays O
. O

Other O
complement O
components O
were O
normal O
during O
remission O
of O
lupus O
, O
but O
C1 O
, O
C4 O
, O
C2 O
, O
and O
C3 O
levels O
fell O
during O
exacerbations O
. O

A O
younger O
half O
- O
sister O
, O
who O
had O
no O
underlying O
disease O
, O
was O
also O
found O
to O
lack O
immunochemically O
detectable O
C5 O
. O

By O
hemolytic O
assay O
, O
she O
exhibited O
1 O
- O
2 O
% O
of O
the O
normal O
serum O
C5 O
level O
and O
normal O
concentrations O
of O
other O
complement O
components O
. O

C5 O
levels O
of O
other O
family O
members O
were O
either O
normal O
or O
approximately O
half O
- O
normal O
, O
consistent O
with O
autosomal O
codominant O
inheritance O
of O
the O
gene O
determining O
C5 B-disease
deficiency I-disease
. O

Normal O
hemolytic O
titers O
were O
restored O
to O
both O
homozygous O
C5 B-disease
- I-disease
deficient I-disease
( O
C5D B-disease
) O
sera O
by O
addition O
of O
highly O
purified O
human O
C5 O
. O

In O
specific O
C5 O
titrations O
, O
however O
, O
it O
was O
noted O
that O
when O
limited O
amounts O
of O
C5 O
were O
assayed O
in O
the O
presence O
of O
low O
dilutions O
of O
either O
C5D B-disease
serum O
, O
curving O
rather O
than O
linear O
dose O
- O
response O
plots O
were O
consistently O
obtained O
, O
suggesting O
some O
inhibitory O
effect O
. O

Further O
studies O
suggested O
that O
low O
dilutions O
of O
C5D B-disease
serum O
contain O
a O
factor O
( O
or O
factors O
) O
interfering O
at O
some O
step O
in O
the O
hemolytic O
assay O
of O
C5 O
, O
rather O
than O
a O
true O
C5 O
inhibitor O
or O
inactivator O
. O

Of O
clinical O
interest O
are O
( O
a O
) O
the O
documentation O
of O
membranous O
glomerulonephritis B-disease
, O
vasculitis B-disease
, O
and O
arthritis B-disease
in O
an O
individual O
lacking O
C5 O
( O
and O
its O
biologic O
functions O
) O
, O
and O
( O
b O
) O
a O
remarkable O
propensity O
to O
bacterial B-disease
infections I-disease
in O
the O
proband O
, O
even O
during O
periods O
of O
low O
- O
dose O
or O
alternate O
- O
day O
corticosteroid O
therapy O
. O

Other O
observations O
indicate O
that O
the O
C5D B-disease
state O
is O
compatible O
with O
normal O
coagulation O
function O
and O
the O
capacity O
to O
mount O
a O
neutrophilic O
leukocytosis O
during O
pyogenic B-disease
infection I-disease
. O
. O

Susceptibility O
to O
ankylosing B-disease
spondylitis I-disease
in O
twins O
: O
the O
role O
of O
genes O
, O
HLA O
, O
and O
the O
environment O
. O

OBJECTIVE O
To O
determine O
the O
relative O
effects O
of O
genetic O
and O
environmental O
factors O
in O
susceptibility O
to O
ankylosing B-disease
spondylitis I-disease
( O
AS B-disease
) O
. O

METHODS O
Twins O
with O
AS B-disease
were O
identified O
from O
the O
Royal O
National O
Hospital O
for O
Rheumatic B-disease
Diseases I-disease
database O
. O

Clinical O
and O
radiographic O
examinations O
were O
performed O
to O
establish O
diagnoses O
, O
and O
disease O
severity O
was O
assessed O
using O
a O
combination O
of O
validated O
scoring O
systems O
. O

HLA O
typing O
for O
HLA O
- O
B27 O
, O
HLA O
- O
B60 O
, O
and O
HLA O
- O
DR1 O
was O
performed O
by O
polymerase O
chain O
reaction O
with O
sequence O
- O
specific O
primers O
, O
and O
zygosity O
was O
assessed O
using O
microsatellite O
markers O
. O

Genetic O
and O
environmental O
variance O
components O
were O
assessed O
with O
the O
program O
Mx O
, O
using O
data O
from O
this O
and O
previous O
studies O
of O
twins O
with O
AS B-disease
. O

RESULTS O
Six O
of O
8 O
monozygotic O
( O
MZ O
) O
twin O
pairs O
were O
disease O
concordant O
, O
compared O
with O
4 O
of O
15 O
B27 O
- O
positive O
dizygotic O
( O
DZ O
) O
twin O
pairs O
( O
27 O
% O
) O
and O
4 O
of O
32 O
DZ O
twin O
pairs O
overall O
( O
12 O
. O
5 O
% O
) O
. O

Nonsignificant O
increases O
in O
similarity O
with O
regard O
to O
age O
at O
disease O
onset O
and O
all O
of O
the O
disease O
severity O
scores O
assessed O
were O
noted O
in O
disease O
- O
concordant O
MZ O
twins O
compared O
with O
concordant O
DZ O
twins O
. O

HLA O
- O
B27 O
and O
B60 O
were O
associated O
with O
the O
disease O
in O
probands O
, O
and O
the O
rate O
of O
disease O
concordance O
was O
significantly O
increased O
among O
DZ O
twin O
pairs O
in O
which O
the O
co O
- O
twin O
was O
positive O
for O
both O
B27 O
and O
DR1 O
. O

Additive O
genetic O
effects O
were O
estimated O
to O
contribute O
97 O
% O
of O
the O
population O
variance O
. O

CONCLUSION O
Susceptibility O
to O
AS B-disease
is O
largely O
genetically O
determined O
, O
and O
the O
environmental O
trigger O
for O
the O
disease O
is O
probably O
ubiquitous O
. O

HLA O
- O
B27 O
accounts O
for O
a O
minority O
of O
the O
overall O
genetic O
susceptibility O
to O
AS B-disease
. O

Cell O
cycle O
- O
dependent O
colocalization O
of O
BARD1 O
and O
BRCA1 O
proteins O
in O
discrete O
nuclear O
domains O
. O

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
gene O
predispose O
women O
to O
early O
- O
onset O
breast B-disease
and I-disease
ovarian I-disease
cancer I-disease
by O
compromising O
the O
genes O
presumptive O
function O
as O
a O
tumor B-disease
suppressor O
. O

Although O
the O
biochemical O
properties O
of O
BRCA1 O
polypeptides O
are O
not O
understood O
, O
their O
expression O
pattern O
and O
subcellular O
localization O
suggest O
a O
role O
in O
cell O
- O
cycle O
regulation O
. O

When O
resting O
cells O
are O
induced O
to O
proliferate O
, O
the O
steady O
- O
state O
levels O
of O
BRCA1 O
increase O
in O
late O
G1 O
and O
reach O
a O
maximum O
during O
S O
phase O
. O

Moreover O
, O
in O
S O
phase O
cells O
, O
BRCA1 O
polypeptides O
are O
hyperphosphorylated O
and O
accumulate O
into O
discrete O
subnuclear O
foci O
termed O
" O
BRCA1 O
nuclear O
dots O
. O

" O
BRCA1 O
associates O
in O
vivo O
with O
a O
structurally O
related O
protein O
termed O
BARD1 O
. O

Here O
we O
show O
that O
the O
steady O
- O
state O
levels O
of O
BARD1 O
, O
unlike O
those O
of O
BRCA1 O
, O
remain O
relatively O
constant O
during O
cell O
cycle O
progression O
. O

However O
, O
immunostaining O
revealed O
that O
BARD1 O
resides O
within O
BRCA1 O
nuclear O
dots O
during O
S O
phase O
of O
the O
cell O
cycle O
, O
but O
not O
during O
the O
G1 O
phase O
. O

Nevertheless O
, O
BARD1 O
polypeptides O
are O
found O
exclusively O
in O
the O
nuclear O
fractions O
of O
both O
G1 O
- O
and O
S O
- O
phase O
cells O
. O

Therefore O
, O
progression O
to O
S O
phase O
is O
accompanied O
by O
the O
aggregation O
of O
nuclear O
BARD1 O
polypeptides O
into O
BRCA1 O
nuclear O
dots O
. O

This O
cell O
cycle O
- O
dependent O
colocalization O
of O
BARD1 O
and O
BRCA1 O
indicates O
a O
role O
for O
BARD1 O
in O
BRCA1 O
- O
mediated O
tumor B-disease
suppression O
. O

Ethnic O
differences O
in O
the O
HFE O
codon O
282 O
( O
Cys O
/ O
Tyr O
) O
polymorphism O
. O

Recent O
studies O
have O
shown O
that O
hereditary B-disease
hemochromatosis I-disease
( O
HH B-disease
) O
is O
likely O
to O
be O
caused O
by O
homozygosity O
for O
a O
Cys282Tyr O
mutation O
in O
the O
HFE O
gene O
located O
4 O
. O

5 O
Mb O
telomeric O
to O
HLA O
- O
A O
. O

Population O
studies O
of O
this O
polymorphism O
are O
facilitated O
by O
the O
fact O
that O
the O
Cys282Tyr O
mutation O
creates O
a O
Rsal O
restriction O
site O
. O

We O
have O
studied O
the O
codon O
282 O
( O
Cys O
/ O
Tyr O
) O
polymorphism O
in O
different O
ethnic O
groups O
. O

In O
agreement O
with O
previous O
observations O
the O
Tyr O
allele O
appeared O
to O
be O
rare O
or O
absent O
in O
Asiatic O
( O
Indian O
, O
Chinese O
) O
populations O
. O

The O
highest O
allele O
frequency O
( O
7 O
. O
5 O
% O
) O
was O
found O
in O
Swedes O
. O

Saamis O
( O
2 O
% O
) O
and O
Mordvinians O
( O
1 O
. O
8 O
% O
) O
had O
significantly O
lower O
frequencies O
of O
the O
Tyr O
allele O
. O

Comparisons O
with O
allele O
frequencies O
based O
on O
prevalence O
estimates O
of O
HH B-disease
showed O
some O
disagreements O
with O
the O
RFLP O
data O
, O
particularly O
in O
Finns O
. O

The O
newly O
described O
HFE O
marker O
provides O
a O
new O
approach O
to O
the O
screening O
of O
HH B-disease
as O
well O
as O
studies O
of O
the O
relationship O
between O
the O
HFE O
Tyr O
allele O
and O
different O
disorders O
including O
cancer B-disease

Autosomal B-disease
dominant I-disease
neurohypophyseal I-disease
diabetes I-disease
insipidus I-disease
associated O
with O
a O
missense O
mutation O
encoding O
Gly23 O
- O
- O
> O
Val O
in O
neurophysin O
II O
. O

Autosomal B-disease
dominant I-disease
neurohypophyseal I-disease
diabetes I-disease
insipidus I-disease
( O
ADNDI B-disease
) O
is O
an O
inherited B-disease
disease I-disease
caused O
by O
progressive O
degeneration O
of O
the O
magnocellular O
neurons O
of O
the O
hypothalamus O
leading O
to O
decreased O
ability O
to O
produce O
the O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
. O

Affected O
individuals O
are O
not O
symptomatic O
at O
birth O
, O
but O
usually O
develop O
diabetes B-disease
insipidus I-disease
at O
1 O
- O
6 O
yr O
of O
age O
. O

The O
genetic O
locus O
of O
the O
disease O
is O
the O
AVP O
- O
neurophysin O
II O
( O
NPII O
) O
gene O
, O
and O
mutations O
that O
cause O
ADNDI B-disease
have O
been O
found O
in O
both O
the O
signal O
peptide O
of O
the O
prepro O
- O
AVP O
- O
NPII O
precursor O
and O
within O
NPII O
itself O
. O

An O
affected O
girl O
who O
presented O
at O
9 O
months O
of O
age O
and O
her O
similarly O
affected O
younger O
brother O
and O
father O
were O
all O
found O
to O
have O
a O
novel O
missense O
mutation O
( O
G1758 O
- O
- O
> O
T O
) O
encoding O
the O
amino O
acid O
substitution O
Gly23 O
- O
- O
> O
Val O
within O
NPII O
. O

The O
mutation O
was O
confirmed O
by O
restriction O
endonuclease O
analysis O
. O

A O
T1 O
- O
weighted O
magnetic O
resonance O
imaging O
of O
the O
fathers O
pituitary O
gland O
demonstrates O
an O
attenuated O
posterior O
pituitary O
bright O
spot O
. O

This O
mutation O
may O
be O
valuable O
for O
developing O
models O
of O
dominantly B-disease
inherited I-disease
neurodegeneration I-disease
, O
as O
the O
early O
age O
of O
onset O
of O
symptoms O
suggests O
that O
this O
mutation O
may O
be O
particularly O
deleterious O
to O
the O
magnocellular O
neuron O
. O
. O

Frequent O
inactivation O
of O
PTEN O
/ O
MMAC1 O
in O
primary O
prostate B-disease
cancer I-disease
. O

Sporadic B-disease
prostate I-disease
carcinoma I-disease
is O
the O
most O
common O
male B-disease
cancer I-disease
in O
the O
Western O
world O
, O
yet O
many O
of O
the O
major O
genetic O
events O
involved O
in O
the O
progression O
of O
this O
often O
fatal O
cancer B-disease
remain O
to O
be O
elucidated O
. O

Numerous O
cytogenetic O
and O
allelotype O
studies O
have O
reported O
frequent O
loss O
of O
heterozygosity O
on O
chromosomal O
arm O
10q O
in O
sporadic B-disease
prostate I-disease
cancer I-disease
. O

Deletion O
mapping O
studies O
have O
unambiguously O
identified O
a O
region O
of O
chromosome O
10q23 O
to O
be O
the O
minimal O
area O
of O
loss O
. O

A O
new O
tumor B-disease
suppressor O
gene O
, O
PTEN O
/ O
MMAC1 O
, O
was O
isolated O
recently O
at O
this O
region O
of O
chromosome O
10q23 O
and O
found O
to O
be O
inactivated O
by O
mutation O
in O
three O
prostate B-disease
cancer I-disease
cell O
lines O
. O

We O
screened O
80 O
prostate B-disease
tumors I-disease
by O
microsatellite O
analysis O
and O
found O
chromosome O
10q23 O
to O
be O
deleted O
in O
23 O
cases O
. O

We O
then O
proceeded O
with O
sequence O
analysis O
of O
the O
entire O
PTEN O
/ O
MMAC1 O
coding O
region O
and O
tested O
for O
homozygous O
deletion O
with O
new O
intragenic O
markers O
in O
these O
23 O
cases O
with O
10q23 O
loss O
of O
heterozygosity O
. O

The O
identification O
of O
the O
second O
mutational O
event O
in O
10 O
( O
43 O
% O
) O
tumors B-disease
establishes O
PTEN O
/ O
MMAC1 O
as O
a O
main O
inactivation O
target O
of O
10q O
loss O
in O
sporadic B-disease
prostate I-disease
cancer I-disease
. O
. O

Risk O
reversals O
in O
predictive O
testing O
for O
Huntington B-disease
disease I-disease
. O

The O
first O
predictive O
testing O
for O
Huntington B-disease
disease I-disease
( O
HD B-disease
) O
was O
based O
on O
analysis O
of O
linked O
polymorphic O
DNA O
markers O
to O
estimate O
the O
likelihood O
of O
inheriting O
the O
mutation O
for O
HD B-disease
. O

Limits O
to O
accuracy O
included O
recombination O
between O
the O
DNA O
markers O
and O
the O
mutation O
, O
pedigree O
structure O
, O
and O
whether O
DNA O
samples O
were O
available O
from O
family O
members O
. O

With O
direct O
tests O
for O
the O
HD B-disease
mutation O
, O
we O
have O
assessed O
the O
accuracy O
of O
results O
obtained O
by O
linkage O
approaches O
when O
requested O
to O
do O
so O
by O
the O
test O
individuals O
. O

For O
six O
such O
individuals O
, O
there O
was O
significant O
disparity O
between O
the O
tests O
. O

Three O
went O
from O
a O
decreased O
risk O
to O
an O
increased O
risk O
, O
while O
in O
another O
three O
the O
risk O
was O
decreased O
. O

Knowledge O
of O
the O
potential O
reasons O
for O
these O
changes O
in O
results O
and O
impact O
of O
these O
risk O
reversals O
on O
both O
patients O
and O
the O
counseling O
team O
can O
assist O
in O
the O
development O
of O
strategies O
for O
the O
prevention O
and O
, O
where O
necessary O
, O
management O
of O
a O
risk O
reversal O
in O
any O
predictive O
testing O
program O
. O
. O

A O
novel O
common O
missense O
mutation O
G301C O
in O
the O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
gene O
in O
mucopolysaccharidosis B-disease
IVA I-disease
. O

Mucopolysaccharidosis B-disease
IVA I-disease
( O
MPS B-disease
IVA I-disease
) O
is O
an O
autosomal B-disease
recessive I-disease
lysosomal I-disease
storage I-disease
disorder I-disease
caused O
by O
a O
genetic B-disease
defect I-disease
in O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
( O
GALNS O
) O
. O

In O
previous O
studies O
, O
we O
have O
found O
two O
common O
mutations O
in O
Caucasians O
and O
Japanese O
, O
respectively O
. O

To O
characterize O
the O
mutational O
spectrum O
in O
various O
ethnic O
groups O
, O
mutations O
in O
the O
GALNS O
gene O
in O
Colombian O
MPS B-disease
IVA I-disease
patients O
were O
investigated O
, O
and O
genetic O
backgrounds O
were O
extensively O
analyzed O
to O
identify O
racial O
origin O
, O
based O
on O
mitochondrial O
DNA O
( O
mtDNA O
) O
lineages O
. O

Three O
novel O
missense O
mutations O
never O
identified O
previously O
in O
other O
populations O
and O
found O
in O
16 O
out O
of O
19 O
Colombian O
MPS B-disease
IVA I-disease
unrelated O
alleles O
account O
for O
84 O
. O

2 O
% O
of O
the O
alleles O
in O
this O
study O
. O

The O
G301C O
and O
S162F O
mutations O
account O
for O
68 O
. O

4 O
% O
and O
10 O
. O

5 O
% O
of O
mutations O
, O
respectively O
, O
whereas O
the O
remaining O
F69V O
is O
limited O
to O
a O
single O
allele O
. O

The O
skewed O
prevalence O
of O
G301C O
in O
only O
Colombian O
patients O
and O
haplotype O
analysis O
by O
restriction O
fragment O
length O
polymorphisms O
in O
the O
GALNS O
gene O
suggest O
that O
G301C O
originated O
from O
a O
common O
ancestor O
. O

Investigation O
of O
the O
genetic O
background O
by O
means O
of O
mtDNA O
lineages O
indicate O
that O
all O
our O
patients O
are O
probably O
of O
native O
American O
descent O

Low O
frequency O
of O
BRCA1 O
germline O
mutations O
in O
45 O
German O
breast B-disease
/ I-disease
ovarian I-disease
cancer I-disease
families O
. O

In O
this O
study O
we O
investigated O
45 O
German O
breast B-disease
/ I-disease
ovarian I-disease
cancer I-disease
families O
for O
germline O
mutations O
in O
the O
BRCA1 O
gene O
. O

We O
identified O
four O
germline O
mutations O
in O
three O
breast B-disease
cancer I-disease
families O
and O
in O
one O
breast B-disease
- I-disease
ovarian I-disease
cancer I-disease
family O
. O
among O
these O
were O
one O
frameshift O
mutation O
, O
one O
nonsense O
mutation O
, O
one O
novel O
splice O
site O
mutation O
, O
and O
one O
missense O
mutation O
. O

The O
missense O
mutation O
was O
also O
found O
in O
2 O
. O

8 O
% O
of O
the O
general O
population O
, O
suggesting O
that O
it O
is O
not O
disease O
associated O
. O

The O
average O
age O
of O
disease O
onset O
in O
those O
families O
harbouring O
causative O
mutations O
was O
between O
32 O
. O

3 O
and O
37 O
. O

4 O
years O
, O
whereas O
the O
family O
harbouring O
the O
missense O
mutation O
had O
an O
average O
age O
of O
onset O
of O
51 O
. O

2 O
years O
. O

These O
findings O
show O
that O
BRCA1 O
is O
implicated O
in O
a O
small O
fraction O
of O
breast B-disease
/ I-disease
ovarian I-disease
cancer I-disease
families O
suggesting O
the O
involvement O
of O
another O
susceptibility O
gene O
( O
s O
) O

Paternal O
transmission O
of O
congenital B-disease
myotonic I-disease
dystrophy I-disease
. O

We O
report O
a O
rare O
case O
of O
paternally O
transmitted O
congenital B-disease
myotonic I-disease
dystrophy I-disease
( O
DM B-disease
) O
. O

The O
proband O
is O
a O
23 O
year O
old O
, O
mentally B-disease
retarded I-disease
male O
who O
suffers O
severe O
muscular B-disease
weakness I-disease
. O

He O
presented O
with O
respiratory O
and O
feeding O
difficulties O
at O
birth O
. O

His O
two O
sibs O
suffer O
from O
childhood O
onset O
DM B-disease
. O

Their O
late O
father O
had O
the O
adult O
type O
of O
DM B-disease
, O
with O
onset O
around O
30 O
years O
. O

Only O
six O
other O
cases O
of O
paternal O
transmission O
of O
congenital B-disease
DM I-disease
have O
been O
reported O
recently O
. O

We O
review O
the O
sex O
related O
effects O
on O
transmission O
of O
congenital B-disease
DM I-disease
. O

Decreased O
fertility O
of O
males O
with O
adult O
onset O
DM B-disease
and O
contraction O
of O
the O
repeat O
upon O
male O
transmission O
contribute O
to O
the O
almost O
absent O
occurrence O
of O
paternal O
transmission O
of O
congenital B-disease
DM I-disease
. O

Also O
the O
fathers O
of O
the O
reported O
congenitally O
affected O
children O
showed O
, O
on O
average O
, O
shorter O
CTG O
repeat O
lengths O
and O
hence O
less O
severe O
clinical O
symptoms O
than O
the O
mothers O
of O
children O
with O
congenital B-disease
DM I-disease
. O

We O
conclude O
that O
paternal O
transmission O
of O
congenital B-disease
DM I-disease
is O
rare O
and O
preferentially O
occurs O
with O
onset O
of O
DM B-disease
past O
30 O
years O
in O
the O
father O
. O
. O

The O
RB1 O
gene O
mutation O
in O
a O
child O
with O
ectopic B-disease
intracranial I-disease
retinoblastoma I-disease
. O

The O
RB1 O
gene O
mutation O
was O
investigated O
in O
a O
child O
with O
ectopic B-disease
intracranial I-disease
retinoblastoma I-disease
using O
DNA O
obtained O
from O
both O
the O
pineal B-disease
and I-disease
retinal I-disease
tumours I-disease
of O
the O
patient O
. O

A O
nonsense O
mutation O
in O
exon O
17 O
( O
codon O
556 O
) O
of O
the O
RB1 O
gene O
was O
found O
to O
be O
present O
homozygously O
in O
both O
the O
retinal B-disease
and I-disease
the I-disease
pineal I-disease
tumours I-disease
. O

The O
same O
mutation O
was O
present O
heterozygously O
in O
the O
DNA O
from O
the O
constitutional O
cells O
of O
the O
patient O
, O
proving O
it O
to O
be O
of O
germline O
origin O
. O

The O
initial O
mutation O
was O
shown O
to O
have O
occurred O
in O
the O
paternally O
derived O
RB1 O
allele O
. O

The O
mutation O
is O
in O
an O
area O
of O
the O
gene O
that O
encodes O
the O
protein O
- O
binding O
region O
known O
as O
the O
pocket O
region O
and O
has O
been O
detected O
in O
other O
cases O
of O
retinoblastoma B-disease
. O
. O

Low O
levels O
of O
beta O
hexosaminidase O
A O
in O
healthy O
individuals O
with O
apparent O
deficiency O
of O
this O
enzyme O
. O

Appreciable O
beta O
hexosaminidase O
A O
( O
hex O
A O
) O
activity O
has O
been O
detected O
in O
cultured O
skin O
fibroblasts O
and O
melanoma B-disease
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B-disease
of I-disease
hex I-disease
A I-disease
activity O
indistinguishable O
from O
that O
of O
patients O
with O
Tay B-disease
- I-disease
Sachs I-disease
disease I-disease
( O
TSD B-disease
) O
. O

Identification O
and O
quantitation O
of O
hex O
A O
, O
amounting O
to O
3 O
. O

5 O
% O
- O
6 O
. O

9 O
% O
of O
total O
beta O
hexosaminidase O
activity O
, O
has O
been O
obtained O
by O
cellulose O
acetate O
gel O
electrophoresis O
, O
DEAE O
- O
cellulose O
ion O
- O
exchange O
chromatography O
, O
radial O
immunodiffusion O
, O
and O
radioimmunoassay O
. O

Previous O
family O
studies O
suggested O
that O
these O
individuals O
may O
be O
compound O
heterozygotes O
for O
the O
common O
mutant O
TSD B-disease
gene O
and O
a O
rare O
( O
allelic O
) O
mutant O
gene O
. O

Thus O
, O
the O
postulated O
rate O
mutant O
gene O
appears O
to O
code O
for O
the O
expression O
of O
low O
amounts O
of O
hex O
A O
. O

Heterozygotes O
for O
the O
rare O
mutant O
may O
be O
indistinguishable O
from O
heterozygotes O
for O
the O
common O
TSD B-disease
mutant O
. O

However O
, O
direct O
visualization O
and O
quantitation O
of O
hex O
A O
by O
the O
methods O
described O
may O
prevent O
false O
- O
positive O
prenatal O
diagnosis O
of O
TSD B-disease
in O
fetuses O
having O
the O
incomplete O
hex B-disease
A I-disease
deficiency I-disease
of O
the O
type O
described O
in O
the O
four O
healthy O
individuals O

The O
tumor B-disease
suppressor O
gene O
Smad4 O
/ O
Dpc4 O
is O
required O
for O
gastrulation O
and O
later O
for O
anterior O
development O
of O
the O
mouse O
embryo O
. O

Mutations O
in O
the O
SMAD4 O
/ O
DPC4 O
tumor B-disease
suppressor O
gene O
, O
a O
key O
signal O
transducer O
in O
most O
TGFbeta O
- O
related O
pathways O
, O
are O
involved O
in O
50 O
% O
of O
pancreatic B-disease
cancers I-disease
. O

Homozygous O
Smad4 O
mutant O
mice O
die O
before O
day O
7 O
. O

5 O
of O
embryogenesis O
. O

Mutant O
embryos O
have O
reduced O
size O
, O
fail O
to O
gastrulate O
or O
express O
a O
mesodermal O
marker O
, O
and O
show O
abnormal O
visceral O
endoderm O
development O
. O

Growth B-disease
retardation I-disease
of O
the O
Smad4 O
- O
deficient O
embryos O
results O
from O
reduced O
cell O
proliferation O
rather O
than O
increased O
apoptosis O
. O

Aggregation O
of O
mutant O
Smad4 O
ES O
cells O
with O
wild O
- O
type O
tetraploid O
morulae O
rescues O
the O
gastrulation B-disease
defect I-disease
. O

These O
results O
indicate O
that O
Smad4 O
is O
initially O
required O
for O
the O
differentiation O
of O
the O
visceral O
endoderm O
and O
that O
the O
gastrulation B-disease
defect I-disease
in O
the O
epiblast O
is O
secondary O
and O
non O
- O
cell O
autonomous O
. O

Rescued O
embryos O
show O
severe O
anterior O
truncations O
, O
indicating O
a O
second O
important O
role O
for O
Smad4 O
in O
anterior O
patterning O
during O
embryogenesis O
. O

Prevalence O
of O
p16 O
and O
CDK4 O
germline O
mutations O
in O
48 O
melanoma B-disease
- O
prone O
families O
in O
France O
. O

The O
French O
Familial B-disease
Melanoma I-disease
Study O
Group O
. O

Germline O
mutations O
in O
the O
p16 O
and O
CDK4 O
genes O
have O
been O
reported O
in O
a O
subset O
of O
melanoma B-disease
pedigrees O
, O
but O
their O
prevalence O
is O
not O
well O
known O
. O

We O
searched O
for O
such O
germline O
mutations O
in O
48 O
French O
melanoma B-disease
- O
prone O
families O
selected O
according O
to O
two O
major O
criteria O
families O
with O
at O
least O
three O
affected O
members O
( O
n O
= O
20 O
) O
or O
families O
with O
two O
affected O
members O
, O
one O
of O
them O
affected O
before O
the O
age O
of O
50 O
( O
n O
= O
28 O
) O
, O
and O
one O
additional O
minor O
criterion O
. O

Sixteen O
different O
p16 O
germline O
mutations O
were O
found O
in O
21 O
families O
, O
while O
one O
germline O
mutation O
, O
Arg24His O
, O
was O
detected O
in O
the O
CDK4 O
gene O
. O

The O
frequency O
of O
p16 O
gene O
mutation O
in O
our O
sample O
( O
44 O
% O
) O
is O
among O
the O
highest O
rates O
yet O
reported O
and O
the O
CDK4 O
mutation O
is O
the O
second O
mutation O
detected O
in O
this O
gene O
worldwide O
. O

In O
summary O
, O
our O
results O
show O
frequent O
involvement O
of O
the O
p16 O
gene O
in O
familial B-disease
melanoma I-disease
and O
confirm O
the O
role O
of O
the O
CDK4 O
gene O
as O
a O
melanoma B-disease
- O
predisposing O
gene O
. O
. O

Progression O
of O
somatic O
CTG O
repeat O
length O
heterogeneity O
in O
the O
blood O
cells O
of O
myotonic B-disease
dystrophy I-disease
patients O
. O

The O
genetic O
basis O
of O
myotonic B-disease
dystrophy I-disease
( O
DM B-disease
) O
is O
the O
expansion O
of O
an O
unstable O
CTG O
repeat O
in O
the O
34 O
UTR O
of O
the O
DM B-disease
protein O
kinase O
gene O
on O
chromosome O
19 O
. O

One O
of O
the O
principal O
features O
of O
the O
DM B-disease
mutation O
is O
an O
extraordinarily O
high O
level O
of O
somatic O
mosaicism O
, O
due O
to O
an O
extremely O
high O
degree O
of O
somatic O
instability O
both O
within O
and O
between O
different O
tissues O
. O

This O
instability O
appears O
to O
be O
biased O
towards O
further O
expansion O
and O
continuous O
throughout O
the O
life O
of O
an O
individual O
, O
features O
that O
could O
be O
associated O
with O
the O
progressive O
nature O
of O
the O
disease O
. O

Although O
increasing O
measured O
allele O
size O
between O
patients O
clearly O
correlates O
with O
an O
increased O
severity O
of O
symptoms O
and O
an O
earlier O
age O
of O
onset O
, O
this O
correlation O
is O
not O
precise O
and O
measured O
allele O
length O
cannot O
be O
used O
as O
an O
accurate O
predictor O
of O
age O
of O
onset O
. O

In O
order O
to O
further O
characterize O
the O
dynamics O
of O
DM B-disease
CTG O
repeat O
somatic O
instability O
, O
we O
have O
studied O
repeat O
length O
changes O
over O
time O
in O
111 O
myotonic B-disease
dystrophy I-disease
patients O
with O
varying O
clinical O
severity O
and O
CTG O
repeat O
size O
over O
time O
intervals O
of O
1 O
- O
7 O
years O
. O

We O
have O
found O
a O
direct O
progression O
of O
the O
size O
heterogeneity O
over O
time O
related O
to O
initial O
CTG O
repeat O
size O
and O
the O
time O
interval O
and O
always O
biased O
towards O
further O
expansion O
. O

Attempts O
to O
mathematically O
model O
the O
dynamics O
have O
proved O
only O
partially O
successful O
suggesting O
that O
individual O
specific O
genetic O
and O
/ O
or O
environmental O
factors O
also O
play O
a O
role O
in O
somatic O
mosaicism O
. O
. O

Aspartylglucosaminuria B-disease
among O
Palestinian O
Arabs O
. O

Aspartylglucosaminuria B-disease
( O
AGU B-disease
) O
is O
a O
rare O
disorder B-disease
of I-disease
glycoprotein I-disease
metabolism I-disease
caused O
by O
the O
deficiency B-disease
of I-disease
the I-disease
lysosomal I-disease
enzyme I-disease
aspartylglucosaminidase I-disease
( O
AGA O
) O
. O

AGU B-disease
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
and O
occurs O
with O
a O
high O
frequency O
in O
Finland O
because O
of O
a O
founder O
effect O
. O

While O
very O
few O
patients O
with O
AGU B-disease
have O
been O
reported O
from O
non O
- O
Finnish O
origin O
, O
we O
diagnosed O
the O
disorder O
in O
8 O
patients O
originating O
from O
3 O
unrelated O
families O
, O
all O
Palestinian O
Arabs O
from O
the O
region O
of O
Jerusalem O
. O

The O
clinical O
diagnosis O
of O
AGU B-disease
is O
often O
difficult O
, O
in O
particular O
early O
in O
the O
course O
of O
the O
disease O
, O
and O
most O
of O
the O
patients O
are O
diagnosed O
after O
the O
age O
of O
5 O
years O
. O

However O
, O
since O
these O
patients O
excrete O
early O
large O
amounts O
of O
aspartylglucosamine O
in O
urine O
, O
biochemical O
screening O
is O
easy O
by O
urine O
chromatography O
. O
. O

Detection O
of O
heterozygous O
carriers O
of O
the O
ataxia B-disease
- I-disease
telangiectasia I-disease
( O
ATM O
) O
gene O
by O
G2 O
phase O
chromosomal O
radiosensitivity O
of O
peripheral O
blood O
lymphocytes O
. O

In O
ataxia B-disease
- I-disease
telangiectasia I-disease
( O
A B-disease
- I-disease
T I-disease
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
ATM O
, O
result O
in O
an O
autosomal B-disease
recessive I-disease
syndrome I-disease
that O
embraces O
a O
variety O
of O
clinical O
features O
and O
manifests O
extreme O
radiosensitivity O
and O
a O
strong O
pre O
- O
disposition O
to O
malignancy B-disease
. O

Heterozygotes O
for O
the O
ATM O
gene O
have O
no O
clinical O
expression O
of O
A B-disease
- I-disease
T I-disease
but O
may O
be O
cancer B-disease
prone O
with O
a O
moderate O
increase O
in O
in O
vitro O
radiosensitivity O
. O

We O
performed O
a O
blind O
chromosomal O
analysis O
on O
G2 O
- O
phase O
lymphocytes O
from O
7 O
unrelated O
A B-disease
- I-disease
T I-disease
patients O
, O
13 O
obligate O
A B-disease
- I-disease
T I-disease
heterozygotes O
( O
parents O
of O
the O
patients O
) O
, O
and O
14 O
normal O
controls O
following O
X O
- O
irradiation O
with O
1 O
Gy O
in O
order O
to O
evaluate O
this O
cytogenetic O
method O
as O
a O
tool O
for O
detection O
of O
ATM O
carriers O
. O

Both O
A B-disease
- I-disease
T I-disease
homozygotes O
and O
heterozygotes O
showed O
significantly O
increased O
levels O
of O
radiation O
- O
induced O
chromatid O
damage O
relative O
to O
that O
of O
normal O
controls O
. O

These O
results O
show O
that O
the O
G2 O
- O
phase O
chromosomal O
radiosensitivity O
assay O
can O
be O
used O
for O
the O
detection O
of O
A B-disease
- I-disease
T I-disease
heterozygotes O
. O

In O
combination O
with O
molecular O
genetic O
analyses O
, O
this O
test O
may O
be O
of O
value O
in O
studies O
of O
familial B-disease
and I-disease
sporadic I-disease
cancers I-disease
aimed O
at O
determination O
of O
the O
potential O
involvement O
of O
ATM O
mutations O
in O
tumor B-disease
risk O
or O
development O
. O
. O

Ataxia B-disease
- I-disease
telangiectasia I-disease
: O
identification O
and O
detection O
of O
founder O
- O
effect O
mutations O
in O
the O
ATM O
gene O
in O
ethnic O
populations O
. O

To O
facilitate O
the O
evaluation O
of O
ATM O
heterozygotes O
for O
susceptibility O
to O
other O
diseases O
, O
such O
as O
breast B-disease
cancer I-disease
, O
we O
have O
attempted O
to O
define O
the O
most O
common O
mutations O
and O
their O
frequencies O
in O
ataxia B-disease
- I-disease
telangiectasia I-disease
( O
A B-disease
- I-disease
T I-disease
) O
homozygotes O
from O
10 O
ethnic O
populations O
. O

Both O
genomic O
mutations O
and O
their O
effects O
on O
cDNA O
were O
characterized O
. O

Protein O
- O
truncation O
testing O
of O
the O
entire O
ATM O
cDNA O
detected O
92 O
( O
66 O
% O
) O
truncating O
mutations O
in O
140 O
mutant O
alleles O
screened O
. O

The O
haplotyping O
of O
patients O
with O
identical O
mutations O
indicates O
that O
almost O
all O
of O
these O
represent O
common O
ancestry O
and O
that O
very O
few O
spontaneously O
recurring O
ATM O
mutations O
exist O
. O

Assays O
requiring O
minimal O
amounts O
of O
genomic O
DNA O
were O
designed O
to O
allow O
rapid O
screening O
for O
common O
ethnic O
mutations O
. O

These O
rapid O
assays O
detected O
mutations O
in O
76 O
% O
of O
Costa O
Rican O
patients O
( O
3 O
) O
, O
50 O
% O
of O
Norwegian O
patients O
( O
1 O
) O
, O
25 O
% O
of O
Polish O
patients O
( O
4 O
) O
, O
and O
14 O
% O
of O
Italian O
patients O
( O
1 O
) O
, O
as O
well O
as O
in O
patients O
of O
Amish O
/ O
Mennonite O
and O
Irish O
English O
backgrounds O
. O

Additional O
mutations O
were O
observed O
in O
Japanese O
, O
Utah O
Mormon O
, O
and O
African O
American O
patients O
. O

These O
assays O
should O
facilitate O
screening O
for O
A B-disease
- I-disease
T I-disease
heterozygotes O
in O
the O
populations O
studied O
. O
. O

The O
von B-disease
Hippel I-disease
- I-disease
Lindau I-disease
tumor I-disease
suppressor O
gene O
is O
required O
for O
cell O
cycle O
exit O
upon O
serum O
withdrawal O
. O

The O
inactivation O
of O
the O
von B-disease
Hippel I-disease
- I-disease
Lindau I-disease
( I-disease
VHL I-disease
) I-disease
tumor I-disease
suppressor O
gene O
predisposes O
affected O
individuals O
to O
the O
human O
VHL B-disease
cancer I-disease
syndrome I-disease
and O
is O
associated O
with O
sporadic B-disease
renal I-disease
cell I-disease
carcinomas I-disease
( O
RCC B-disease
) O
and O
brain B-disease
hemangioblastomas I-disease
. O

VHL O
- O
negative O
786 O
- O
0 O
RCC B-disease
cells O
are O
tumorigenic O
in O
nude O
mice O
which O
is O
suppressed O
by O
the O
reintroduction O
of O
VHL B-disease
. O

Remarkably O
, O
this O
occurs O
without O
affecting O
the O
growth O
rate O
and O
cell O
cycle O
profile O
of O
these O
cells O
in O
culture O
. O

The O
786 O
- O
0 O
cell O
line O
, O
like O
many O
cancer B-disease
cells O
, O
fails O
to O
exit O
the O
cell O
cycle O
upon O
serum O
withdrawal O
. O

Here O
, O
it O
is O
shown O
that O
reintroduction O
of O
the O
wild O
- O
type O
VHL B-disease
gene O
restores O
the O
ability O
of O
VHL O
- O
negative O
RCC B-disease
cancer I-disease
cells O
to O
exit O
the O
cell O
cycle O
and O
enter O
G0 O
/ O
quiescence O
in O
low O
serum O
. O

Both O
VHL O
- O
positive O
and O
VHL O
- O
negative O
RCC B-disease
cells O
exit O
the O
cell O
cycle O
by O
contact O
inhibition O
. O

The O
cyclin O
- O
dependent O
kinase O
inhibitor O
, O
p27 O
, O
accumulates O
upon O
serum O
withdrawal O
, O
only O
in O
the O
presence O
of O
VHL B-disease
, O
as O
a O
result O
of O
the O
stabilization O
of O
the O
protein O
. O

We O
propose O
that O
the O
loss O
of O
wild O
- O
type O
VHL B-disease
gene O
results O
in O
a O
specific O
cellular O
defect O
in O
serum O
- O
dependent O
growth O
control O
, O
which O
may O
initiate O
tumor B-disease
formation O
. O

This O
is O
corrected O
by O
the O
reintroduction O
of O
wild O
- O
type O
VHL B-disease
, O
implicating O
VHL B-disease
as O
the O
first O
tumor B-disease
suppressor O
involved O
in O
the O
regulation O
of O
cell O
cycle O
exit O
, O
which O
is O
consistent O
with O
its O
gatekeeper O
function O
in O
the O
kidney O
. O
. O

Piebaldism B-disease
with O
deafness B-disease
: O
molecular O
evidence O
for O
an O
expanded O
syndrome O
. O

In O
a O
South O
African O
girl O
of O
Xhosa O
stock O
with O
severe O
piebaldism B-disease
and O
profound O
congenital O
sensorineural B-disease
deafness I-disease
we O
identified O
a O
novel O
missense O
substitution O
at O
a O
highly O
conserved O
residue O
in O
the O
intracellular O
kinase O
domain O
of O
the O
KIT O
proto O
- O
oncogene O
, O
R796G O
. O

Though O
auditory B-disease
anomalies I-disease
have O
been O
observed O
in O
mice O
with O
dominant O
white O
spotting O
( O
W O
) O
due O
to O
KIT O
mutations O
, O
deafness B-disease
is O
not O
typical O
in O
human O
piebaldism B-disease
. O

Thus O
, O
the O
occurrence O
of O
sensorineural B-disease
deafness I-disease
in O
this O
patient O
extends O
considerably O
the O
phenotypic O
range O
of O
piebaldism B-disease
due O
to O
KIT O
gene O
mutation O
in O
humans O
and O
tightens O
the O
clinical O
similarity O
between O
piebaldism B-disease
and O
the O
various O
forms O
of O
Waardenburg B-disease
syndrome I-disease
. O
. O

Cycloheximide O
facilitates O
the O
identification O
of O
aberrant O
transcripts O
resulting O
from O
a O
novel O
splice O
- O
site O
mutation O
in O
COL17A1 O
in O
a O
patient O
with O
generalized O
atrophic B-disease
benign I-disease
epidermolysis I-disease
bullosa I-disease
. O

Patients O
with O
generalized O
atrophic B-disease
benign I-disease
epidermolysis I-disease
bullosa I-disease
often O
show O
decreased O
expression O
of O
type O
XVII O
collagen O
, O
a O
transmembrane O
hemidesmosomal O
protein O
encoded O
by O
COL17A1 O
. O

This O
report O
documents O
a O
novel O
splice O
- O
site O
mutation O
in O
COL17A1 O
in O
a O
patient O
with O
generalized O
atrophic B-disease
benign I-disease
epidermolysis I-disease
bullosa I-disease
, O
and O
applies O
a O
new O
methodology O
to O
define O
and O
characterize O
the O
resulting O
mRNA O
splice O
variants O
. O

Mutational O
analysis O
of O
COL17A1 O
identified O
a O
maternally O
inherited O
G O
- O
to O
- O
T O
transversion O
at O
the O
- O
1 O
position O
of O
exon O
32 O
. O

This O
acceptor O
splice O
- O
site O
mutation O
led O
to O
the O
formation O
of O
aberrant O
transcripts O
present O
at O
extremely O
low O
levels O
. O

Based O
on O
our O
recent O
finding O
that O
cycloheximide O
stabilized O
mutant O
COL17A1 O
transcripts O
in O
keratinocytes O
homozygous O
for O
a O
frameshift O
mutation O
, O
the O
effects O
of O
the O
splice O
- O
site O
mutation O
on O
splicing O
of O
COL17A1 O
transcripts O
were O
determined O
using O
reverse O
transcriptase O
polymerase O
chain O
reaction O
of O
total O
RNA O
from O
keratinocytes O
incubated O
for O
2 O
. O

5 O
h O
in O
the O
presence O
or O
absence O
of O
10 O
microg O
cycloheximide O
per O
ml O
. O

Using O
this O
approach O
, O
an O
abnormally O
spliced O
transcript O
was O
identified O
that O
contains O
an O
extra O
264 O
bases O
upstream O
from O
exon O
32 O
, O
resulting O
in O
a O
premature O
termination O
codon O
27 O
bp O
downstream O
from O
the O
cryptic O
splice O
site O
. O

Three O
other O
splice O
variants O
, O
including O
one O
derived O
from O
the O
skipping O
of O
exon O
32 O
, O
were O
also O
identified O
. O

These O
results O
indicate O
the O
usefulness O
of O
cycloheximide O
treatment O
in O
evaluating O
the O
abnormal O
processing O
of O
mRNA O
due O
to O
splice O
- O
site O
mutations O
, O
because O
( O
i O
) O
aberrant O
splicing O
often O
generates O
a O
premature O
termination O
codon O
, O
( O
ii O
) O
transcripts O
with O
premature O
termination O
codons O
can O
occur O
at O
low O
or O
undetectable O
levels O
due O
to O
nonsense O
- O
mediated O
mRNA O
decay O
, O
and O
( O
iii O
) O
the O
levels O
of O
these O
transcripts O
can O
be O
increased O
by O
cycloheximide O
. O

A O
deletion O
mutation O
in O
COL17A1 O
in O
five O
Austrian O
families O
with O
generalized O
atrophic B-disease
benign I-disease
epidermolysis I-disease
bullosa I-disease
represents O
propagation O
of O
an O
ancestral O
allele O
. O

Patients O
with O
generalized O
atrophic B-disease
benign I-disease
epidermolysis I-disease
bullosa I-disease
, O
a O
usually O
nonlethal O
form O
of O
junctional B-disease
epidermolysis I-disease
bullosa I-disease
, O
have O
generalized O
blistering B-disease
, O
nail B-disease
dystrophy I-disease
, O
patchy B-disease
alopecia I-disease
, O
and O
dental B-disease
abnormalities I-disease
. O

Skin B-disease
fragility I-disease
in O
most O
cases O
is O
due O
to O
mutations O
in O
the O
gene O
encoding O
type O
XVII O
collagen O
( O
COL17A1 O
) O
. O

Recently O
, O
we O
reported O
five O
Austrian O
families O
with O
generalized O
atrophic B-disease
benign I-disease
epidermolysis I-disease
bullosa I-disease
who O
share O
the O
same O
COL17A1 O
mutation O
. O

Affected O
individuals O
in O
three O
families O
are O
homozygous O
for O
4003delTC O
, O
whereas O
those O
in O
two O
others O
are O
compound O
heterozygotes O
. O

To O
determine O
if O
the O
occurrence O
of O
4003delTC O
in O
these O
unrelated O
families O
signifies O
propagation O
of O
an O
ancestral O
allele O
or O
a O
mutational O
hot O
spot O
, O
haplotypes O
were O
determined O
for O
polymorphisms O
both O
within O
and O
flanking O
COL17A1 O
. O

Five O
intragenic O
polymorphisms O
were O
chosen O
based O
on O
their O
informativeness O
. O

One O
of O
these O
, O
not O
previously O
reported O
, O
was O
2988 O
A O
or O
C O
that O
introduces O
a O
new O
restriction O
site O
for O
Eco0109 O
I O
. O

All O
the O
4003delTC O
alleles O
showed O
the O
same O
haplotype O
for O
these O
five O
polymorphic O
markers O
. O

Fourteen O
microsatellite O
polymorphisms O
were O
selected O
based O
on O
their O
high O
heterozygosity O
and O
their O
location O
within O
10q23 O
- O
q25 O
near O
COL17A1 O
. O

Three O
families O
shared O
microsatellite O
polymorphisms O
covering O
at O
most O
19 O
cM O
, O
whereas O
the O
others O
shared O
smaller O
regions O
consistent O
with O
cross O
- O
over O
events O
during O
passage O
of O
this O
mutation O
through O
several O
generations O
. O

These O
results O
indicate O
that O
4003delTC O
occurs O
on O
a O
single O
ancestral O
allele O
. O
. O

The O
haptoglobin O
- O
gene O
deletion O
responsible O
for O
anhaptoglobinemia B-disease
. O

We O
have O
found O
an O
allelic O
deletion O
of O
the O
haptoglobin O
( O
Hp O
) O
gene O
from O
an O
individual O
with O
anhaptoglobinemia B-disease
. O

The O
Hp O
gene O
cluster O
consists O
of O
coding O
regions O
of O
the O
alpha O
chain O
and O
beta O
chain O
of O
the O
haptoglobin O
gene O
( O
Hp O
) O
and O
of O
the O
alpha O
chain O
and O
beta O
chain O
of O
the O
haptoglobin O
- O
related O
gene O
( O
Hpr O
) O
, O
in O
tandem O
from O
the O
5 O
side O
. O

Southern O
blot O
and O
PCR O
analyses O
have O
indicated O
that O
the O
individual O
with O
anhaptoglobinemia B-disease
was O
homozygous O
for O
the O
gene O
deletion O
and O
that O
the O
gene O
deletion O
was O
included O
at O
least O
from O
the O
promoter O
region O
of O
Hp O
to O
Hpr O
alpha O
but O
not O
to O
Hpr O
beta O
( O
Hpdel O
) O
. O

In O
addition O
, O
we O
found O
seven O
individuals O
with O
hypohaptoglobinemia B-disease
in O
three O
families O
, O
and O
the O
genotypes O
of O
six O
of O
the O
seven O
individuals O
were O
found O
to O
be O
Hp2 O
/ O
Hpdel O
. O

The O
phenotypes O
and O
genotypes O
in O
one O
of O
these O
three O
families O
showed O
the O
father O
to O
be O
hypohaptoglobinemic B-disease
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
the O
mother O
to O
be O
Hp2 O
- O
1 O
and O
Hp1 O
/ O
Hp2 O
, O
one O
of O
the O
two O
children O
to O
be O
hypohaptoglobinemic B-disease
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
and O
the O
other O
child O
to O
be O
Hp1 O
and O
Hp1 O
/ O
Hpdel O
, O
showing O
an O
anomalous O
inheritance O
of O
Hp O
phenotypes O
in O
the O
child O

with O
Hp1 O
. O

The O
Hp2 O
/ O
Hpdel O
individuals O
had O
an O
extremely O
low O
level O
of O
Hp O
( O
mean O
+ O
/ O
- O
SD O
= O
0 O
. O
049 O
+ O
/ O
- O
0 O
. O
043 O
mg O
/ O
ml O
; O
n O
= O
6 O
) O
, O
compared O
with O
the O
level O
( O
1 O
. O
64 O
+ O
/ O
- O
1 O
. O
07 O
mg O
/ O
ml O
) O
obtained O
from O
52 O
healthy O
volunteers O
having O
phenotype O
Hp2 O
, O
whereas O
the O
serum O
Hp O
level O
of O
an O
individual O
with O
Hp1 O
/ O
Hpdel O
was O
0 O
. O

50 O
mg O
/ O
ml O
, O
which O
was O
approximately O
half O
the O
level O
of O
Hp O
in O
control O
sera O
from O
the O
Hp1 O
phenotype O
( O
1 O
. O
26 O
+ O
/ O
- O
0 O
. O
33 O
mg O
/ O
ml O
; O
n O
= O
9 O
) O
, O
showing O
a O
gene O
- O
dosage O
effect O
. O

The O
other O
allele O
( O
Hp2 O
) O
of O
individuals O
with O
Hp2 O
/ O
Hpdel O
was O
found O
to O
have O
, O
in O
all O
exons O
, O
no O
mutation O
, O
by O
DNA O
sequencing O
. O

On O
the O
basis O
of O
the O
present O
study O
, O
the O
mechanism O
of O
anhaptoglobinemia B-disease
and O
the O
mechanism O
of O
anomalous O
inheritance O
of O
Hp O
phenotypes O
were O
well O
explained O
. O

However O
, O
the O
mechanism O
of O
hypohaptoglobinemia B-disease
remains O
unknown O

ATM O
mutations O
and O
phenotypes O
in O
ataxia B-disease
- I-disease
telangiectasia I-disease
families O
in O
the O
British O
Isles O
: O
expression O
of O
mutant O
ATM O
and O
the O
risk O
of O
leukemia B-disease
, O
lymphoma B-disease
, O
and O
breast B-disease
cancer I-disease
. O

We O
report O
the O
spectrum O
of O
59 O
ATM O
mutations O
observed O
in O
ataxia B-disease
- I-disease
telangiectasia I-disease
( O
A B-disease
- I-disease
T I-disease
) O
patients O
in O
the O
British O
Isles O
. O

Of O
51 O
ATM O
mutations O
identified O
in O
families O
native O
to O
the O
British O
Isles O
, O
11 O
were O
founder O
mutations O
, O
and O
2 O
of O
these O
11 O
conferred O
a O
milder O
clinical O
phenotype O
with O
respect O
to O
both O
cerebellar B-disease
degeneration I-disease
and O
cellular O
features O
. O

We O
report O
, O
in O
two O
A B-disease
- I-disease
T I-disease
families O
, O
an O
ATM O
mutation O
( O
7271T O
- O
- O
> O
G O
) O
that O
may O
be O
associated O
with O
an O
increased O
risk O
of O
breast B-disease
cancer I-disease
in O
both O
homozygotes O
and O
heterozygotes O
( O
relative O
risk O
12 O
. O
7 O
; O
P O
= O
. O
0025 O
) O
, O
although O
there O
is O
a O
less O
severe O
A B-disease
- I-disease
T I-disease
phenotype O
in O
terms O
of O
the O
degree O
of O
cerebellar B-disease
degeneration I-disease
. O

This O
mutation O
( O
7271T O
- O
- O
> O
G O
) O
also O
allows O
expression O
of O
full O
- O
length O
ATM O
protein O
at O
a O
level O
comparable O
with O
that O
in O
unaffected O
individuals O
. O

In O
addition O
, O
we O
have O
studied O
18 O
A B-disease
- I-disease
T I-disease
patients O
, O
in O
15 O
families O
, O
who O
developed O
leukemia B-disease
, O
lymphoma B-disease
, O
preleukemic O
T O
- O
cell O
proliferation O
, O
or O
Hodgkin B-disease
lymphoma I-disease
, O
mostly O
in O
childhood O
. O

A O
wide O
variety O
of O
ATM O
mutation O
types O
, O
including O
missense O
mutations O
and O
in O
- O
frame O
deletions O
, O
were O
seen O
in O
these O
patients O
. O

We O
also O
show O
that O
25 O
% O
of O
all O
A B-disease
- I-disease
T I-disease
patients O
carried O
in O
- O
frame O
deletions O
or O
missense O
mutations O
, O
many O
of O
which O
were O
also O
associated O
with O
expression O
of O
mutant O
ATM O
protein O
. O

The O
DMPK O
gene O
of O
severely O
affected O
myotonic B-disease
dystrophy I-disease
patients O
is O
hypermethylated O
proximal O
to O
the O
largely O
expanded O
CTG O
repeat O
. O

Using O
methylation O
- O
sensitive O
restriction O
enzymes O
, O
we O
characterized O
the O
methylation O
pattern O
on O
the O
5 O
side O
of O
the O
CTG O
repeat O
in O
the O
DMPK O
gene O
of O
normal O
individuals O
and O
of O
patients O
affected O
with O
myotonic B-disease
dystrophy I-disease
, O
showing O
expansions O
of O
the O
repetitive O
sequence O
. O

The O
gene O
segment O
analyzed O
corresponds O
to O
the O
genomic O
SacI O
- O
HindIII O
fragment O
carrying O
exons O
11 O
- O
15 O
. O

There O
is O
constitutive O
methylation O
in O
intron O
12 O
at O
restriction O
sites O
of O
SacII O
and O
HhaI O
, O
localized O
1 O
, O
159 O
- O
1 O
, O
232 O
bp O
upstream O
of O
the O
CTG O
repeat O
, O
whereas O
most O
, O
if O
not O
all O
, O
of O
the O
other O
sites O
of O
SacII O
, O
HhaI O
, O
and O
HpaII O
in O
this O
region O
are O
unmethylated O
, O
in O
normal O
individuals O
and O
most O
of O
the O
patients O
. O

In O
a O
number O
of O
young O
and O
severely O
affected O
patients O
, O
however O
, O
complete O
methylation O
of O
these O
restriction O
sites O
was O
found O
in O
the O
mutated O
allele O
. O

In O
most O
of O
these O
patients O
, O
the O
onset O
of O
the O
disease O
was O
congenital O
. O

Preliminary O
in O
vivo O
footprinting O
data O
gave O
evidence O
for O
protein O
- O
DNA O
contact O
in O
normal O
genes O
at O
an O
Sp1 O
consensus O
binding O
site O
upstream O
of O
the O
CTG O
repeat O
and O
for O
a O
significant O
reduction O
of O
this O
interaction O
in O
cells O
with O
a O
hypermethylated O
DMPK O
gene O
. O
. O

The O
hemochromatosis B-disease
gene O
product O
complexes O
with O
the O
transferrin O
receptor O
and O
lowers O
its O
affinity O
for O
ligand O
binding O
. O

We O
recently O
reported O
the O
positional O
cloning O
of O
a O
candidate O
gene O
for O
hereditary B-disease
hemochromatosis I-disease
called O
HFE O
. O

The O
gene O
product O
, O
a O
member O
of O
the O
major O
histocompatibility O
complex O
class O
I O
- O
like O
family O
, O
was O
found O
to O
have O
a O
mutation O
, O
Cys O
- O
282 O
- O
- O
> O
Tyr O
( O
C282Y O
) O
, O
in O
85 O
% O
of O
patient O
chromosomes O
. O

This O
mutation O
eliminates O
the O
ability O
of O
HFE O
to O
associate O
with O
beta2 O
- O
microglobulin O
( O
beta2m O
) O
and O
prevents O
cell O
- O
surface O
expression O
. O

A O
second O
mutation O
that O
has O
no O
effect O
on O
beta2m O
association O
, O
H63D O
, O
was O
found O
in O
eight O
out O
of O
nine O
patients O
heterozygous O
for O
the O
C282Y O
mutant O
. O

In O
this O
report O
, O
we O
demonstrate O
in O
cultured O
293 O
cells O
overexpressing O
wild O
- O
type O
or O
mutant O
HFE O
proteins O
that O
both O
the O
wild O
- O
type O
and O
H63D O
HFE O
proteins O
form O
stable O
complexes O
with O
the O
transferrin O
receptor O
( O
TfR O
) O
. O

The O
C282Y O
mutation O
nearly O
completely O
prevents O
the O
association O
of O
the O
mutant O
HFE O
protein O
with O
the O
TfR O
. O

Studies O
on O
cell O
- O
associated O
transferrin O
at O
37 O
degrees O
C O
suggest O
that O
the O
overexpressed O
wild O
- O
type O
HFE O
protein O
decreases O
the O
affinity O
of O
the O
TfR O
for O
transferrin O
. O

The O
overexpressed O
H63D O
protein O
does O
not O
have O
this O
effect O
, O
providing O
the O
first O
direct O
evidence O
for O
a O
functional O
consequence O
of O
the O
H63D O
mutation O
. O

Addition O
of O
soluble O
wild O
- O
type O
HFE O
/ O
beta2m O
heterodimers O
to O
cultured O
cells O
also O
decreased O
the O
apparent O
affinity O
of O
the O
TfR O
for O
its O
ligand O
under O
steady O
- O
state O
conditions O
, O
both O
in O
293 O
cells O
and O
in O
HeLa O
cells O
. O

Furthermore O
, O
at O
4 O
degrees O
C O
, O
the O
added O
soluble O
complex O
of O
HFE O
/ O
beta2m O
inhibited O
binding O
of O
transferrin O
to O
HeLa O
cell O
TfR O
in O
a O
concentration O
- O
dependent O
manner O
. O

Scatchard O
plots O
of O
these O
data O
indicate O
that O
the O
added O
heterodimer O
substantially O
reduced O
the O
affinity O
of O
TfR O
for O
transferrin O
. O

These O
results O
establish O
a O
molecular O
link O
between O
HFE O
and O
a O
key O
protein O
involved O
in O
iron O
transport O
, O
the O
TfR O
, O
and O
raise O
the O
possibility O
that O
alterations O
in O
this O
regulatory O
mechanism O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
hereditary B-disease
hemochromatosis I-disease
. O
. O

Genomic O
organization O
of O
the O
UBE3A O
/ O
E6 O
- O
AP O
gene O
and O
related O
pseudogenes O
. O

The O
UBE3A O
gene O
encodes O
the O
E6 O
- O
AP O
ubiquitin O
- O
protein O
ligase O
and O
has O
recently O
been O
shown O
to O
be O
mutated O
in O
Angelman B-disease
syndrome I-disease
patients O
who O
lack O
15q11 O
- O
q13 O
deletions O
or O
chromosome O
15 O
paternal O
uniparental B-disease
disomy I-disease
. O

Previous O
UBE3A O
cDNA O
analysis O
has O
shown O
a O
coding O
region O
of O
approximately O
2 O
. O

6 O
kb O
and O
a O
3 O
- O
untranslated O
region O
( O
UTR O
) O
of O
< O
50 O
bp O
, O
whereas O
Northern O
analysis O
has O
indicated O
mRNA O
sizes O
of O
5 O
- O
8 O
kb O
. O

We O
have O
analyzed O
additional O
cDNA O
clones O
and O
provide O
evidence O
for O
an O
additional O
0 O
. O

5 O
kb O
of O
5 O
- O
UTR O
and O
> O
2 O
kb O
of O
3 O
- O
UTR O
. O

We O
have O
established O
the O
genomic O
organization O
of O
UBE3A O
and O
the O
sequence O
of O
intron O
- O
exon O
borders O
. O

We O
have O
also O
mapped O
two O
highly O
homologous O
processed O
pseudogenes O
, O
UBE3AP1 O
and O
UBE3AP2 O
, O
to O
chromosomes O
2 O
and O
21 O
, O
respectively O
, O
and O
determined O
their O
genomic O
organization O
. O

These O
results O
will O
form O
the O
basis O
for O
studies O
of O
mutation O
and O
imprinting O
of O
UBE3A O
. O

Mutation O
spectrum O
and O
genotype O
- O
phenotype O
analyses O
in O
Cowden B-disease
disease I-disease
and O
Bannayan B-disease
- I-disease
Zonana I-disease
syndrome I-disease
, O
two O
hamartoma B-disease
syndromes I-disease
with O
germline O
PTEN O
mutation O
. O

The O
tumour B-disease
suppressor O
gene O
PTEN O
, O
which O
maps O
to O
10q23 O
. O

3 O
and O
encodes O
a O
403 O
amino O
acid O
dual O
specificity O
phosphatase O
( O
protein O
tyrosine O
phosphatase O
; O
PTPase O
) O
, O
was O
shown O
recently O
to O
play O
a O
broad O
role O
in O
human O
malignancy B-disease
. O

Somatic O
PTEN O
deletions O
and O
mutations O
were O
observed O
in O
sporadic B-disease
breast I-disease
, I-disease
brain I-disease
, I-disease
prostate I-disease
and I-disease
kidney I-disease
cancer I-disease
cell O
lines O
and O
in O
several O
primary O
tumours B-disease
such O
as O
endometrial B-disease
carcinomas I-disease
, O
malignant B-disease
melanoma I-disease
and O
thyroid B-disease
tumours I-disease
. O

In O
addition O
, O
PTEN O
was O
identified O
as O
the O
susceptibility O
gene O
for O
two O
hamartoma B-disease
syndromes I-disease
Cowden B-disease
disease I-disease
( O
CD B-disease
; O
MIM O
158350 O
) O
and O
Bannayan B-disease
- I-disease
Zonana I-disease
( I-disease
BZS I-disease
) I-disease
or I-disease
Ruvalcaba I-disease
- I-disease
Riley I-disease
- I-disease
Smith I-disease
syndrome I-disease
( O
MIM O
153480 O
) O
. O

Constitutive O
DNA O
from O
37 O
CD B-disease
families O
and O
seven O
BZS B-disease
families O
was O
screened O
for O
germline O
PTEN O
mutations O
. O

PTEN O
mutations O
were O
identified O
in O
30 O
of O
37 O
( O
81 O
% O
) O
CD B-disease
families O
, O
including O
missense O
and O
nonsense O
point O
mutations O
, O
deletions O
, O
insertions O
, O
a O
deletion O
/ O
insertion O
and O
splice O
site O
mutations O
. O

These O
mutations O
were O
scattered O
over O
the O
entire O
length O
of O
PTEN O
, O
with O
the O
exception O
of O
the O
first O
, O
fourth O
and O
last O
exons O
. O

A O
hot O
spot O
for O
PTEN O
mutation O
in O
CD B-disease
was O
identified O
in O
exon O
5 O
that O
contains O
the O
PTPase O
core O
motif O
, O
with O
13 O
of O
30 O
( O
43 O
% O
) O
CD B-disease
mutations O
identified O
in O
this O
exon O
. O

Seven O
of O
30 O
( O
23 O
% O
) O
were O
within O
the O
core O
motif O
, O
the O
majority O
( O
five O
of O
seven O
) O
of O
which O
were O
missense O
mutations O
, O
possibly O
pointing O
to O
the O
functional O
significance O
of O
this O
region O
. O

Germline O
PTEN O
mutations O
were O
identified O
in O
four O
of O
seven O
( O
57 O
% O
) O
BZS B-disease
families O
studied O
. O

Interestingly O
, O
none O
of O
these O
mutations O
was O
observed O
in O
the O
PTPase O
core O
motif O
. O

It O
is O
also O
worthy O
of O
note O
that O
a O
single O
nonsense O
point O
mutation O
, O
R233X O
, O
was O
observed O
in O
the O
germline O
DNA O
from O
two O
unrelated O
CD B-disease
families O
and O
one O
BZS B-disease
family O
. O

Genotype O
- O
phenotype O
studies O
were O
not O
performed O
on O
this O
small O
group O
of O
BZS B-disease
families O
. O

However O
, O
genotype O
- O
phenotype O
analysis O
inthe O
group O
of O
CD B-disease
families O
revealed O
two O
possible O
associations O
worthy O
of O
follow O
- O
up O
in O
independent O
analyses O
. O

The O
first O
was O
an O
association O
noted O
in O
the O
group O
of O
CD B-disease
families O
with O
breast B-disease
disease I-disease
. O

A O
correlation O
was O
observed O
between O
the O
presence O
/ O
absence O
of O
a O
PTEN O
mutation O
and O
the O
type O
of O
breast O
involvement O
( O
unaffected O
versus O
benign O
versus O
malignant O
) O
. O

Specifically O
and O
more O
directly O
, O
an O
association O
was O
also O
observed O
between O
the O
presence O
of O
a O
PTEN O
mutation O
and O
malignant B-disease
breast I-disease
disease I-disease
. O

Secondly O
, O
there O
appeared O
to O
be O
an O
interdependent O
association O
between O
mutations O
upstream O
and O
within O
the O
PTPase O
core O
motif O
, O
the O
core O
motif O
containing O
the O
majority O
of O
missense O
mutations O
, O
and O
the O
involvement O
of O
all O
major O
organ O
systems O
( O
central O
nervous O
system O
, O
thyroid O
, O
breast O
, O
skin O
and O
gastrointestinal O
tract O
) O
. O

However O
, O
these O
observations O
would O
need O
to O
be O
confirmed O
by O
studying O
a O
larger O
number O
of O
CD B-disease
families O
. O

Molecular O
defects O
leading O
to O
human O
complement B-disease
component I-disease
C6 I-disease
deficiency I-disease
in O
an O
African O
- O
American O
family O
. O

Complement B-disease
component I-disease
C6 I-disease
deficiency I-disease
( O
C6D B-disease
) O
was O
diagnosed O
in O
a O
16 O
- O
year O
- O
old O
African O
- O
American O
male O
with O
meningococcal B-disease
meningitis I-disease
. O

The O
patients O
father O
and O
two O
brothers O
also O
had O
C6D B-disease
, O
but O
gave O
no O
history O
of O
meningitis B-disease
or O
other O
neisserial B-disease
infection I-disease
. O

By O
using O
exon O
- O
specific O
polymerase O
chain O
reaction O
( O
PCR O
) O
/ O
single O
- O
strand O
conformation O
polymorphism O
as O
a O
screening O
step O
and O
nucleotide O
sequencing O
of O
target O
exons O
, O
we O
determined O
that O
the O
proband O
was O
a O
compound O
heterozygote O
for O
two O
C6 O
gene O
mutations O
. O

The O
first O
, O
1195delC O
located O
in O
exon O
7 O
, O
is O
a O
novel O
mutation O
, O
while O
the O
second O
, O
1936delG O
in O
exon O
12 O
, O
has O
been O
described O
before O
to O
cause O
C6D B-disease
in O
an O
unrelated O
African O
- O
American O
individual O
. O

Both O
mutations O
result O
in O
premature O
termination O
codons O
and O
C6 O
null O
alleles O
. O

Allele O
- O
specific O
PCR O
indicated O
that O
the O
probands O
two O
brothers O
also O
inherited O
the O
1195delC O
mutation O
from O
their O
heterozygous O
mother O
and O
the O
1936delG O
mutation O
from O
their O
homozygous O
father O
. O
. O

PAX6 O
mutations O
reviewed O
. O

Mutations O
in O
PAX6 O
are O
responsible O
for O
human O
aniridia B-disease
and O
have O
also O
been O
found O
in O
patients O
with O
Peters B-disease
anomaly I-disease
, O
with O
congenital B-disease
cataracts I-disease
, O
with O
autosomal B-disease
dominant I-disease
keratitis I-disease
, O
and O
with O
isolated B-disease
foveal I-disease
hypoplasia I-disease
. O

No O
locus O
other O
than O
chromosome O
11p13 O
has O
been O
implicated O
in O
aniridia B-disease
, O
and O
PAX6 O
is O
clearly O
the O
major O
, O
if O
not O
only O
, O
gene O
responsible O
. O

Twenty O
- O
eight O
percent O
of O
identified O
PAX6 O
mutations O
are O
C O
- O
T O
changes O
at O
CpG O
dinucleotides O
, O
20 O
% O
are O
splicing O
errors O
, O
and O
more O
than O
30 O
% O
are O
deletion O
or O
insertion O
events O
. O

There O
is O
a O
noticeably O
elevated O
level O
of O
mutation O
in O
the O
paired O
domain O
compared O
with O
the O
rest O
of O
the O
gene O
. O

Increased O
mutation O
in O
the O
homeodomain O
is O
accounted O
for O
by O
the O
hypermutable O
CpG O
dinucleotide O
in O
codon O
240 O
. O

Very O
nearly O
all O
mutations O
appear O
to O
cause O
loss O
of O
function O
of O
the O
mutant O
allele O
, O
and O
more O
than O
80 O
% O
of O
exonic O
substitutions O
result O
in O
nonsense O
codons O
. O

In O
a O
gene O
with O
such O
extraordinarily O
high O
sequence O
conservation O
throughout O
evolution O
, O
there O
are O
presumed O
undiscovered O
missense O
mutations O
, O
these O
are O
hypothesized O
to O
exist O
in O
as O
- O
yet O
unidentified O
phenotypes O
. O
. O

Genetic O
heterogeneity O
and O
penetrance O
analysis O
of O
the O
BRCA1 O
and O
BRCA2 O
genes O
in O
breast B-disease
cancer I-disease
families O
. O

The O
Breast B-disease
Cancer I-disease
Linkage O
Consortium O
. O

The O
contribution O
of O
BRCA1 O
and O
BRCA2 O
to O
inherited B-disease
breast I-disease
cancer I-disease
was O
assessed O
by O
linkage O
and O
mutation O
analysis O
in O
237 O
families O
, O
each O
with O
at O
least O
four O
cases O
of O
breast B-disease
cancer I-disease
, O
collected O
by O
the O
Breast B-disease
Cancer I-disease
Linkage O
Consortium O
. O

Families O
were O
included O
without O
regard O
to O
the O
occurrence O
of O
ovarian B-disease
or I-disease
other I-disease
cancers I-disease
. O

Overall O
, O
disease O
was O
linked O
to O
BRCA1 O
in O
an O
estimated O
52 O
% O
of O
families O
, O
to O
BRCA2 O
in O
32 O
% O
of O
families O
, O
and O
to O
neither O
gene O
in O
16 O
% O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
6 O
% O
- O
28 O
% O
) O
, O
suggesting O
other O
predisposition O
genes O
. O

The O
majority O
( O
81 O
% O
) O
of O
the O
breast B-disease
- I-disease
ovarian I-disease
cancer I-disease
families O
were O
due O
to O
BRCA1 O
, O
with O
most O
others O
( O
14 O
% O
) O
due O
to O
BRCA2 O
. O

Conversely O
, O
the O
majority O
of O
families O
with O
male B-disease
and I-disease
female I-disease
breast I-disease
cancer I-disease
were O
due O
to O
BRCA2 O
( O
76 O
% O
) O
. O

The O
largest O
proportion O
( O
67 O
% O
) O
of O
families O
due O
to O
other O
genes O
was O
found O
in O
families O
with O
four O
or O
five O
cases O
of O
female O
breast B-disease
cancer I-disease
only O
. O

These O
estimates O
were O
not O
substantially O
affected O
either O
by O
changing O
the O
assumed O
penetrance O
model O
for O
BRCA1 O
or O
by O
including O
or O
excluding O
BRCA1 O
mutation O
data O
. O

Among O
those O
families O
with O
disease O
due O
to O
BRCA1 O
that O
were O
tested O
by O
one O
of O
the O
standard O
screening O
methods O
, O
mutations O
were O
detected O
in O
the O
coding O
sequence O
or O
splice O
sites O
in O
an O
estimated O
63 O
% O
( O
95 O
% O
CI O
51 O
% O
- O
77 O
% O
) O
. O

The O
estimated O
sensitivity O
was O
identical O
for O
direct O
sequencing O
and O
other O
techniques O
. O

The O
penetrance O
of O
BRCA2 O
was O
estimated O
by O
maximizing O
the O
LOD O
score O
in O
BRCA2 O
- O
mutation O
families O
, O
over O
all O
possible O
penetrance O
functions O
. O

The O
estimated O
cumulative O
risk O
of O
breast B-disease
cancer I-disease
reached O
28 O
% O
( O
95 O
% O
CI O
9 O
% O
- O
44 O
% O
) O
by O
age O
50 O
years O
and O
84 O
% O
( O
95 O
% O
CI O
43 O
% O
- O
95 O
% O
) O
by O
age O
70 O
years O
. O

The O
corresponding O
ovarian B-disease
cancer I-disease
risks O
were O
0 O
. O

4 O
% O
( O
95 O
% O
CI O
0 O
% O
- O
1 O
% O
) O
by O
age O
50 O
years O
and O
27 O
% O
( O
95 O
% O
CI O
0 O
% O
- O
47 O
% O
) O
by O
age O
70 O
years O
. O

The O
lifetime O
risk O
of O
breast B-disease
cancer I-disease
appears O
similar O
to O
the O
risk O
in O
BRCA1 O
carriers O
, O
but O
there O
was O
some O
suggestion O
of O
a O
lower O
risk O
in O
BRCA2 O
carriers O
< O
50 O
years O
of O
age O
. O

Eye B-disease
movement I-disease
abnormalities I-disease
correlate O
with O
genotype O
in O
autosomal O
dominant O
cerebellar B-disease
ataxia I-disease
type I-disease
I I-disease
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B-disease
ataxias I-disease
type I-disease
I I-disease
spinocerebellar B-disease
ataxias I-disease
1 I-disease
and I-disease
2 I-disease
( O
SCA1 B-disease
, O
n O
= O
11 O
; O
SCA2 B-disease
, O
n O
= O
10 O
) O
and O
SCA3 B-disease
/ O
Machado B-disease
- I-disease
Joseph I-disease
disease I-disease
( O
MJD B-disease
) O
( O
n O
= O
16 O
) O
. O

In O
SCA1 B-disease
, O
saccade O
amplitude O
was O
significantly O
increased O
, O
resulting O
in O
hypermetria B-disease
. O

The O
smooth O
pursuit O
gain O
was O
decreased O
. O

In O
SCA2 B-disease
, O
saccade O
velocity O
was O
markedly O
decreased O
. O

The O
percentage O
of O
errors O
in O
antisaccades O
was O
greatly O
increased O
and O
was O
significantly O
correlated O
with O
age O
at O
disease O
onset O
. O

In O
addition O
, O
a O
correlation O
between O
smooth O
pursuit O
gain O
and O
the O
number O
of O
trinucleotide O
repeats O
was O
found O
. O

In O
SCA3 B-disease
, O
gaze B-disease
- I-disease
evoked I-disease
nystagmus I-disease
was O
often O
present O
as O
was O
saccade O
hypometria O
and O
smooth O
pursuit O
gain O
was O
markedly O
decreased O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B-disease
- I-disease
evoked I-disease
nystagmus I-disease
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B-disease
, O
90 O
% O
of O
the O
SCA2 B-disease
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B-disease
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
orient O
diagnoses O
of O
SCA1 B-disease
, O
SCA2 B-disease
, O
and O
SCA3 B-disease
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

Genetic O
basis O
and O
molecular O
mechanism O
for O
idiopathic B-disease
ventricular I-disease
fibrillation I-disease
. O

Ventricular B-disease
fibrillation I-disease
causes O
more O
than O
300 O
, O
000 O
sudden O
deaths O
each O
year O
in O
the O
USA O
alone O
. O

In O
approximately O
5 O
- O
12 O
% O
of O
these O
cases O
, O
there O
are O
no O
demonstrable O
cardiac O
or O
non O
- O
cardiac O
causes O
to O
account O
for O
the O
episode O
, O
which O
is O
therefore O
classified O
as O
idiopathic B-disease
ventricular I-disease
fibrillation I-disease
( O
IVF B-disease
) O
. O

A O
distinct O
group O
of O
IVF B-disease
patients O
has O
been O
found O
to O
present O
with O
a O
characteristic O
electrocardiographic O
pattern O
. O

Because O
of O
the O
small O
size O
of O
most O
pedigrees O
and O
the O
high O
incidence O
of O
sudden B-disease
death I-disease
, O
however O
, O
molecular O
genetic O
studies O
of O
IVF B-disease
have O
not O
yet O
been O
done O
. O

Because O
IVF B-disease
causes O
cardiac O
rhythm O
disturbance O
, O
we O
investigated O
whether O
malfunction O
of O
ion O
channels O
could O
cause O
the O
disorder O
by O
studying O
mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
SCN5A O
. O

We O
have O
now O
identified O
a O
missense O
mutation O
, O
a O
splice O
- O
donor O
mutation O
, O
and O
a O
frameshift O
mutation O
in O
the O
coding O
region O
of O
SCN5A O
in O
three O
IVF B-disease
families O
. O

We O
show O
that O
sodium O
channels O
with O
the O
missense O
mutation O
recover O
from O
inactivation O
more O
rapidly O
than O
normal O
and O
that O
the O
frameshift O
mutation O
causes O
the O
sodium O
channel O
to O
be O
non O
- O
functional O
. O

Our O
results O
indicate O
that O
mutations O
in O
cardiac O
ion O
- O
channel O
genes O
contribute O
to O
the O
risk O
of O
developing O
IVF B-disease
. O
. O

Molecular O
heterogeneity O
in O
mucopolysaccharidosis B-disease
IVA I-disease
in O
Australia O
and O
Northern O
Ireland O
: O
nine O
novel O
mutations O
including O
T312S O
, O
a O
common O
allele O
that O
confers O
a O
mild O
phenotype O
. O

Mucopolysaccharidosis B-disease
IVA I-disease
( O
MPS B-disease
IVA I-disease
) O
is O
an O
autosomal B-disease
recessive I-disease
lysosomal I-disease
storage I-disease
disorder I-disease
caused O
by O
a O
genetic B-disease
defect I-disease
in O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
( O
GALNS O
) O
. O

Previous O
studies O
of O
patients O
from O
a O
British O
- O
Irish O
population O
showed O
that O
the O
I113F O
mutation O
is O
the O
most O
common O
single O
mutation O
among O
MPS B-disease
IVA I-disease
patients O
and O
produces O
a O
severe O
clinical O
phenotype O
. O

We O
studied O
mutations O
in O
the O
GALNS O
gene O
from O
23 O
additional O
MPS B-disease
IVA I-disease
patients O
( O
15 O
from O
Australia O
, O
8 O
from O
Northern O
Ireland O
) O
, O
with O
various O
clinical O
phenotypes O
( O
severe O
, O
16 O
cases O
; O
intermediate O
, O
4 O
cases O
; O
mild O
, O
3 O
cases O
) O
. O

We O
found O
two O
common O
mutations O
that O
together O
accounted O
for O
32 O
% O
of O
the O
44 O
unrelated O
alleles O
in O
these O
patients O
. O

One O
is O
the O
T312S O
mutation O
, O
a O
novel O
mutation O
found O
exclusively O
in O
milder O
patients O
. O

The O
other O
is O
the O
previously O
described O
I113F O
that O
produces O
a O
severe O
phenotype O
. O

The O
I113F O
and O
T312S O
mutations O
accounted O
for O
8 O
( O
18 O
% O
) O
and O
6 O
( O
14 O
% O
) O
of O
44 O
unrelated O
alleles O
, O
respectively O
. O

The O
relatively O
high O
residual O
GALNS O
activity O
seen O
when O
the O
T312S O
mutant O
cDNA O
is O
overexpressed O
in O
mutant O
cells O
provides O
an O
explanation O
for O
the O
mild O
phenotype O
in O
patients O
with O
this O
mutation O
. O

The O
distribution O
and O
relative O
frequencies O
of O
the O
I113F O
and O
T312S O
mutations O
in O
Australia O
corresponded O
to O
those O
observed O
in O
Northern O
Ireland O
and O
are O
unique O
to O
these O
two O
populations O
, O
suggesting O
that O
both O
mutations O
were O
probably O
introduced O
to O
Australia O
by O
Irish O
migrants O
during O
the O
19th O
century O
. O

Haplotype O
analysis O
using O
6 O
RFLPs O
provides O
additional O
data O
that O
the O
I113F O
mutation O
originated O
from O
a O
common O
ancestor O
. O

The O
other O
9 O
novel O
mutations O
identified O
in O
these O
23 O
patients O
were O
each O
limited O
to O
a O
single O
family O
. O

These O
data O
provide O
further O
evidence O
for O
extensive O
allelic O
heterogeneity O
in O
MPS B-disease
IVA I-disease
in O
British O
- O
Irish O
patients O
and O
provide O
evidence O
for O
their O
transmission O
to O
Australia O
by O
British O
- O
Irish O
migrants O
. O
. O

Identification O
of O
constitutional O
WT1 O
mutations O
, O
in O
patients O
with O
isolated O
diffuse B-disease
mesangial I-disease
sclerosis I-disease
, O
and O
analysis O
of O
genotype O
/ O
phenotype O
correlations O
by O
use O
of O
a O
computerized O
mutation O
database O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B-disease
- I-disease
Drash I-disease
syndrome I-disease
( O
DDS B-disease
) O
, O
or O
diffuse B-disease
mesangial I-disease
sclerosis I-disease
( O
DMS B-disease
) O
associated O
with O
pseudohermaphroditism B-disease
and O
/ O
or O
Wilms B-disease
tumor I-disease
( O
WT B-disease
) O
. O

Most O
mutations O
in O
DDS B-disease
patients O
lie O
in O
exon O
8 O
or O
exon O
9 O
, O
encoding O
zinc O
finger O
2 O
or O
zinc O
finger O
3 O
, O
respectively O
, O
with O
a O
hot O
spot O
( O
R394W O
) O
in O
exon O
9 O
. O

We O
analyzed O
a O
series O
of O
24 O
patients O
, O
10 O
with O
isolated B-disease
DMS I-disease
( O
IDMS B-disease
) O
, O
10 O
with O
DDS B-disease
, O
and O
4 O
with O
urogenital B-disease
abnormalities I-disease
and O
/ O
or O
WT B-disease
. O

We O
report O
WT1 O
heterozygous O
mutations O
in O
16 O
patients O
, O
4 O
of O
whom O
presented O
with O
IDMS B-disease
. O

One O
male O
and O
two O
female O
IDMS B-disease
patients O
with O
WT1 O
mutations O
underwent O
normal O
puberty O
. O

Two O
mutations O
associated O
with O
IDMS B-disease
are O
different O
from O
those O
described O
in O
DDS B-disease
patients O
. O

No O
WT1 O
mutations O
were O
detected O
in O
the O
six O
other O
IDMS B-disease
patients O
, O
suggesting O
genetic O
heterogeneity O
of O
this O
disease O
. O

We O
analyzed O
genotype O
/ O
phenotype O
correlations O
, O
on O
the O
basis O
of O
the O
constitution O
of O
a O
WT1 O
mutation O
database O
of O
84 O
germ O
- O
line O
mutations O
, O
to O
compare O
the O
distribution O
and O
type O
of O
mutations O
, O
according O
to O
the O
different O
symptoms O
. O

This O
demonstrated O
( O
1 O
) O
the O
association O
between O
mutations O
in O
exons O
8 O
and O
9 O
and O
DMS B-disease
; O
( O
2 O
) O
among O
patients O
with O
DMS B-disease
, O
a O
higher O
frequency O
of O
exon O
8 O
mutations O
among O
46 O
, O
XY O
patients O
with O
female O
phenotype O
than O
among O
46 O
, O
XY O
patients O
with O
sexual O
ambiguity O
or O
male O
phenotype O
; O
and O
( O
3 O
) O
statistically O
significant O
evidence O
that O
mutations O
in O
exons O
8 O
and O
9 O
preferentially O
affect O
amino O
acids O
with O
different O
functions O
. O
. O

The O
185delAG O
BRCA1 O
mutation O
originated O
before O
the O
dispersion O
of O
Jews O
in O
the O
diaspora O
and O
is O
not O
limited O
to O
Ashkenazim O
. O

The O
185delAG O
mutation O
in O
BRCA1 O
is O
detected O
in O
Ashkenazi O
Jews O
both O
in O
familial B-disease
breast I-disease
and I-disease
ovarian I-disease
cancer I-disease
and O
in O
the O
general O
population O
. O

All O
tested O
Ashkenazi O
mutation O
carriers O
share O
the O
same O
allelic O
pattern O
at O
the O
BRCA1 O
locus O
. O

Our O
previous O
study O
showed O
that O
this O
Ashkenazi O
mutation O
also O
occurs O
in O
Iraqi O
Jews O
with O
a O
similar O
allelic O
pattern O
. O

We O
extended O
our O
analysis O
to O
other O
non O
- O
Ashkenazi O
subsets O
354 O
of O
Moroccan O
origin O
, O
200 O
Yemenites O
and O
150 O
Iranian O
Jews O
. O

Heteroduplex O
analysis O
complemented O
by O
direct O
DNA O
sequencing O
of O
abnormally O
migrating O
bands O
were O
employed O
. O

Four O
of O
Moroccan O
origin O
( O
1 O
. O
1 O
% O
) O
and O
none O
of O
the O
Yemenites O
or O
Iranians O
was O
a O
carrier O
of O
the O
185delAG O
mutation O
. O

BRCA1 O
allelic O
patterns O
were O
determined O
for O
four O
of O
these O
individuals O
and O
for O
12 O
additional O
non O
- O
Ashkenazi O
185delAG O
mutation O
carriers O
who O
had O
breast B-disease
/ I-disease
ovarian I-disease
cancer I-disease
. O

Six O
non O
- O
Ashkenazi O
individuals O
shared O
the O
common O
Ashkenazi O
haplotype O
, O
four O
had O
a O
closely O
related O
pattern O
, O
and O
the O
rest O
( O
n O
= O
6 O
) O
displayed O
a O
distinct O
BRCA1 O
allelic O
pattern O
. O

We O
conclude O
that O
the O
185delAG O
BRCA1 O
mutation O
occurs O
in O
some O
non O
- O
Ashkenazi O
populations O
at O
rates O
comparable O
with O
that O
of O
Ashkenazim O
. O

The O
majority O
of O
Jewish O
185delAG O
mutation O
carriers O
have O
a O
common O
allelic O
pattern O
, O
supporting O
the O
founder O
effect O
notion O
, O
but O
dating O
the O
mutations O
origin O
to O
an O
earlier O
date O
than O
currently O
estimated O
. O

However O
, O
the O
different O
allelic O
pattern O
at O
the O
BRCA1 O
locus O
even O
in O
some O
Jewish O
mutation O
carriers O
, O
might O
suggest O
that O
the O
mutation O
arose O
independently O
. O
. O

Crystal O
structure O
of O
the O
hemochromatosis B-disease
protein O
HFE O
and O
characterization O
of O
its O
interaction O
with O
transferrin O
receptor O
. O

HFE O
is O
an O
MHC O
- O
related O
protein O
that O
is O
mutated O
in O
the O
iron B-disease
- I-disease
overload I-disease
disease I-disease
hereditary B-disease
hemochromatosis I-disease
. O

HFE O
binds O
to O
transferrin O
receptor O
( O
TfR O
) O
and O
reduces O
its O
affinity O
for O
iron O
- O
loaded O
transferrin O
, O
implicating O
HFE O
in O
iron O
metabolism O
. O

The O
2 O
. O

6 O
A O
crystal O
structure O
of O
HFE O
reveals O
the O
locations O
of O
hemochromatosis B-disease
mutations O
and O
a O
patch O
of O
histidines O
that O
could O
be O
involved O
in O
pH O
- O
dependent O
interactions O
. O

We O
also O
demonstrate O
that O
soluble O
TfR O
and O
HFE O
bind O
tightly O
at O
the O
basic O
pH O
of O
the O
cell O
surface O
, O
but O
not O
at O
the O
acidic O
pH O
of O
intracellular O
vesicles O
. O

TfR O
HFE O
stoichiometry O
( O
2 O
1 O
) O
differs O
from O
TfR O
transferrin O
stoichiometry O
( O
2 O
2 O
) O
, O
implying O
a O
different O
mode O
of O
binding O
for O
HFE O
and O
transferrin O
to O
TfR O
, O
consistent O
with O
our O
demonstration O
that O
HFE O
, O
transferrin O
, O
and O
TfR O
form O
a O
ternary O
complex O
. O

Identification O
of O
three O
novel O
mutations O
and O
a O
high O
frequency O
of O
the O
Arg778Leu O
mutation O
in O
Korean O
patients O
with O
Wilson B-disease
disease I-disease
. O

Four O
mutations O
- O
- O
R778L O
, O
A874V O
, O
L1083F O
, O
and O
2304delC O
- O
- O
in O
the O
copper O
- O
transporting O
enzyme O
, O
P O
- O
type O
ATPase O
( O
ATP7B O
) O
, O
were O
identified O
in O
Korean O
Patients O
with O
Wilson B-disease
disease I-disease
. O

Arg778Leu O
, O
the O
most O
frequently O
reported O
mutation O
of O
this O
enzyme O
, O
was O
found O
in O
six O
of O
eight O
unrelated O
patients O
studied O
, O
an O
allele O
frequency O
of O
37 O
. O

5 O
% O
, O
which O
is O
considerably O
higher O
than O
those O
in O
other O
Asian O
populations O
. O

The O
novel O
single O
nucleotide O
deletion O
, O
2304delC O
, O
was O
found O
in O
one O
patient O
. O

Since O
a O
mutation O
at O
cDNA O
nucleotide O
2302 O
( O
2302insC O
) O
had O
been O
previously O
described O
, O
this O
region O
of O
the O
ATP7B O
gene O
may O
be O
susceptible O
to O
gene O
rearrangements O
causing O
Wilson B-disease
disease I-disease
. O

Disruption O
of O
splicing O
regulated O
by O
a O
CUG O
- O
binding O
protein O
in O
myotonic B-disease
dystrophy I-disease
. O

Myotonic B-disease
dystrophy I-disease
( O
DM B-disease
) O
is O
caused O
by O
a O
CTG O
expansion O
in O
the O
3 O
untranslated O
region O
of O
the O
DM B-disease
gene O
. O

One O
model O
of O
DM B-disease
pathogenesis O
suggests O
that O
RNAs O
from O
the O
expanded O
allele O
create O
a O
gain O
- O
of O
- O
function O
mutation O
by O
the O
inappropriate O
binding O
of O
proteins O
to O
the O
CUG O
repeats O
. O

Data O
presented O
here O
indicate O
that O
the O
conserved O
heterogeneous O
nuclear O
ribonucleoprotein O
, O
CUG O
- O
binding O
protein O
( O
CUG O
- O
BP O
) O
, O
may O
mediate O
the O
trans O
- O
dominant O
effect O
of O
the O
RNA O
. O

CUG O
- O
BP O
was O
found O
to O
bind O
to O
the O
human O
cardiac O
troponin O
T O
( O
cTNT O
) O
pre O
- O
messenger O
RNA O
and O
regulate O
its O
alternative O
splicing O
. O

Splicing O
of O
cTNT O
was O
disrupted O
in O
DM B-disease
striated O
muscle O
and O
in O
normal O
cells O
expressing O
transcripts O
that O
contain O
CUG O
repeats O
. O

Altered O
expression O
of O
genes O
regulated O
posttranscriptionally O
by O
CUG O
- O
BP O
therefore O
may O
contribute O
to O
DM B-disease
pathogenesis O
. O
. O

Identification O
of O
a O
novel O
nonsense O
mutation O
and O
a O
missense O
substitution O
in O
the O
vasopressin O
- O
neurophysin O
II O
gene O
in O
two O
Spanish O
kindreds O
with O
familial B-disease
neurohypophyseal I-disease
diabetes I-disease
insipidus I-disease
. O

Familial B-disease
neurohypophyseal I-disease
diabetes I-disease
insipidus I-disease
( O
FNDI B-disease
) O
is O
an O
autosomal B-disease
dominant I-disease
disease I-disease
caused O
by O
deficiency O
in O
the O
antidiuretic O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
encoded O
by O
the O
AVP O
- O
neurophysin O
II O
( O
AVP O
- O
NPII O
) O
gene O
on O
chromosome O
20p13 O
. O

In O
this O
study O
, O
we O
analyzed O
two O
families O
with O
FNDI B-disease
using O
direct O
automated O
fluorescent O
, O
solid O
phase O
, O
single O
- O
stranded O
DNA O
sequencing O
of O
PCR O
- O
amplified O
AVP O
- O
NPII O
DNA O
. O

In O
one O
of O
the O
families O
, O
affected O
individuals O
presented O
a O
novel O
nonsense O
mutation O
in O
exon O
3 O
of O
the O
gene O
, O
consisting O
in O
a O
G O
to O
T O
transition O
at O
nucleotide O
2101 O
, O
which O
produces O
a O
stop O
signal O
in O
codon O
82 O
( O
Glu O
) O
of O
NPII O
. O

The O
premature O
termination O
eliminates O
part O
of O
the O
C O
- O
terminal O
domain O
of O
NPII O
, O
including O
a O
cysteine O
residue O
in O
position O
85 O
, O
which O
could O
be O
involved O
in O
the O
correct O
folding O
of O
the O
prohormone O
. O

In O
the O
second O
family O
, O
a O
G279A O
substitution O
at O
position O
- O
1 O
of O
the O
signal O
peptide O
was O
observed O
in O
all O
affected O
individuals O
. O

This O
missense O
mutation O
, O
which O
replaces O
Ala O
with O
Thr O
, O
is O
frequent O
among O
FNDI B-disease
patients O
and O
is O
thought O
to O
reduce O
the O
efficiency O
of O
cleavage O
by O
signal O
peptidases O
. O
. O

Genetic O
heterogeneity O
of O
Saethre B-disease
- I-disease
Chotzen I-disease
syndrome I-disease
, O
due O
to O
TWIST O
and O
FGFR O
mutations O
. O

Thirty O
- O
two O
unrelated O
patients O
with O
features O
of O
Saethre B-disease
- I-disease
Chotzen I-disease
syndrome I-disease
, O
a O
common O
autosomal B-disease
dominant I-disease
condition I-disease
of O
craniosynostosis B-disease
and O
limb B-disease
anomalies I-disease
, O
were O
screened O
for O
mutations O
in O
TWIST O
, O
FGFR2 O
, O
and O
FGFR3 O
. O

Nine O
novel O
and O
three O
recurrent O
TWIST O
mutations O
were O
found O
in O
12 O
families O
. O

Seven O
families O
were O
found O
to O
have O
the O
FGFR3 O
P250R O
mutation O
, O
and O
one O
individual O
was O
found O
to O
have O
an O
FGFR2 O
VV269 O
- O
270 O
deletion O
. O

To O
date O
, O
our O
detection O
rate O
for O
TWIST O
or O
FGFR O
mutations O
is O
68 O
% O
in O
our O
Saethre B-disease
- I-disease
Chotzen I-disease
syndrome I-disease
patients O
, O
including O
our O
five O
patients O
elsewhere O
reported O
with O
TWIST O
mutations O
. O

More O
than O
35 O
different O
TWIST O
mutations O
are O
now O
known O
in O
the O
literature O
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
TWIST O
mutations O
, O
are O
coronal B-disease
synostosis I-disease
, O
brachycephaly B-disease
, O
low B-disease
frontal I-disease
hairline I-disease
, O
facial B-disease
asymmetry I-disease
, O
ptosis B-disease
, O
hypertelorism B-disease
, O
broad B-disease
great I-disease
toes I-disease
, O
and O
clinodactyly B-disease
. O

Significant O
intra O
- O
and O
interfamilial O
phenotypic O
variability O
is O
present O
for O
either O
TWIST O
mutations O
or O
FGFR O
mutations O
. O

The O
overlap O
in O
clinical O
features O
and O
the O
presence O
, O
in O
the O
same O
genes O
, O
of O
mutations O
for O
more O
than O
one O
craniosynostotic B-disease
condition I-disease
- O
such O
as O
Saethre B-disease
- I-disease
Chotzen I-disease
, I-disease
Crouzon I-disease
, I-disease
and I-disease
Pfeiffer I-disease
syndromes I-disease
- O
support O
the O
hypothesis O
that O
TWIST O
and O
FGFRs O
are O
components O
of O
the O
same O
molecular O
pathway O
involved O
in O
the O
modulation O
of O
craniofacial O
and O
limb O
development O
in O
humans O
. O
. O

Mutation O
analysis O
of O
UBE3A O
in O
Angelman B-disease
syndrome I-disease
patients O
. O

Angelman B-disease
syndrome I-disease
( O
AS B-disease
) O
is O
caused O
by O
chromosome O
15q11 O
- O
q13 O
deletions O
of O
maternal O
origin O
, O
by O
paternal O
uniparental B-disease
disomy I-disease
( O
UPD B-disease
) O
15 O
, O
by O
imprinting O
defects O
, O
and O
by O
mutations O
in O
the O
UBE3A O
gene O
. O

UBE3A O
encodes O
a O
ubiquitin O
- O
protein O
ligase O
and O
shows O
brain O
- O
specific O
imprinting O
. O

Here O
we O
describe O
UBE3A O
coding O
- O
region O
mutations O
detected O
by O
SSCP O
analysis O
in O
13 O
AS B-disease
individuals O
or O
families O
. O

Two O
identical O
de O
novo O
5 O
- O
bp O
duplications O
in O
exon O
16 O
were O
found O
. O

Among O
the O
other O
11 O
unique O
mutations O
, O
8 O
were O
small O
deletions O
or O
insertions O
predicted O
to O
cause O
frameshifts O
, O
1 O
was O
a O
mutation O
to O
a O
stop O
codon O
, O
1 O
was O
a O
missense O
mutation O
, O
and O
1 O
was O
predicted O
to O
cause O
insertion O
of O
an O
isoleucine O
in O
the O
hect O
domain O
of O
the O
UBE3A O
protein O
, O
which O
functions O
in O
E2 O
binding O
and O
ubiquitin O
transfer O
. O

The O
MS/MS O
spectrum O
of O
PE B-lipid
(42:4) I-lipid
is O
shown O
in O
the O
, O
which O
showed O
the O
characteristic O
product O
ion O
due O
to O
the O
loss O
of O
141 O
Da O
(ethanolaminephosphate) O
from O
the O
[M+H]_+ O
ion, O
and O
this O
ion O
known O
to O
be O
specific O
for O
PE O
[,]. O

Plasma O
lipids O
specific O
to O
obesity‐related O
insulin O
resistance O
(i.e., O
different O
between O
OIS O
and O
OIR, O
but O
not O
between O
OIR O
and O
Lean) O
included O
DG(14:1_16:0), B-lipid
CE(22:4) B-lipid
and O
PC(O‐35:4) O
(higher) O
and O
Hex2Cer(d18:1/22:0), O
Hex2Cer(d18:1/24:0) O
and O
LPC(22:0) B-lipid
(lower). O

Measurements O
of O
lipids O
composed O
of O
two O
fatty O
acids O
are O
determined O
as O
the O
sum O
of O
the O
carbons O
and O
the O
double O
bonds O
across O
both O
fatty O
acids, O
e.g. O
PC(36:4) B-lipid
based O
on O
previous O
methods O
(Weir O
et O
al. O
; O

According O
to O
univariate O
statistics, O
the O
following O
compounds O
were O
significantly O
different O
between O
samples O
from O
the O
pre-symptomatic O
individuals O
and O
controls: O
oleic O
acid O
(p O
= O
0.040, O
AUROC O
= O
0.67), O
β-hydroxypalmitic O
acid O
(p O
= O
0.049, O
AUROC O
= O
0.67), O
kynurenine O
(p O
= O
0.015, O
AUROC O
= O
0.66), O
hypoxanthine O
(p O
= O
0.044, O
AUROC O
= O
0.69), O
LPC(16:0) B-lipid
(p O
= O
0.049, O
AUROC O
= O
0.69), O
LPC(14:0) B-lipid
(p O
= O
0.012, O
AUROC O
= O
0.70) O
and O
3-indolelactic O
acid O
(p O
= O
0.045, O
AUROC O
= O
0.65). O

This O
analysis O
failed O
to O
discern O
differences O
among O
the O
3 O
groups O
in O
their O
regioisomeric O
composition; O
the O
14,15-EET B-lipid
predominated O
and O
the O
11,12-EET B-lipid
was O
least. O

also O
show O
chromatograms O
of O
the O
second O
mass O
transitions O
of O
m/z O
622 O
to O
282 O
for O
Cer(22:0) B-lipid
and O
m/z O
650 O
to O
282 O
for O
Cer(24:0), B-lipid
respectively, O
that O
were O
used O
for O
purposes O
of O
confirmation. O

Changes O
in O
lactosylceramide O
correlated O
positively O
with O
△ O
decanoylcarnitine O
and O
negatively O
with O
△ O
L-valine, O
△ O
lysoPCs O
(14:0, O
16:0, O
18:2, O
18:0, O
20:3, O
and O
22:6), O
and O
△ O
PC B-lipid
(18:0/20:4) I-lipid
(r O
= O
0.266, O
P O
= O
0.004). O

We O
observed O
here O
SM(36:3) B-lipid
as O
a O
marker O
of O
TFA O
intake. O

A O
discontinuous O
gradient O
was O
generated O
to O
resolve O
the O
analytes O
by O
mixing O
solvent O
A O
(0.1% O
propionic B-lipid
acid I-lipid
in O
water) O
with O
solvent O
B O
(0.1% O
acetic O
acid O
in O
methanol). O

20-HETE B-lipid
producing O
CYP450 O
isoform O
specific O
primer O
sequences O
were O
as O
follows: O
CYP4A11-F O
(ATGAAGTGTGCCTTCAGCCA), O
CYP4A11-R O
(AAG O
GCATTCC O
TCACACGGG), O
CYP4A22-F O
(AATGGGAAGAGCTCCTTGGC), O
CYP4A22-R O
(AAGGCATTCCTCATACAGC), O
CYP4F2-F O
(AAGCA O
CCCAGAATACCAGGA), O
CYP4F2-R O
(TCATGCACA O
TGGTCAG O
GAAG), O
CYP4F3-F(CTGTCGGCAGGAGGTACAAG), O
CYP4F3-R O
(CCTCAGGCTCTCCTTAATGC). O

Regarding O
phosphatidylglycerol O
(PGs), O
which O
a O
phosphoglycerol O
moiety O
occupies O
a O
glycerol O
substitution O
site, O
little O
evidence O
has O
been O
shown O
on O
their O
relationship O
with O
CHD, O
and O
we O
were O
the O
first O
to O
reveal O
a O
positive O
relationship O
between O
PG(20:3/2:0) B-lipid
and O
CHD O
(OR: O
3.938; O
95% O
CI: O
(1.891, O
8.204); O

Of O
the O
nine O
PCs O
associated O
with O
obesity, O
seven O
were O
available O
for O
replication O
and O
five O
(71%), O
including O
PC B-lipid
(38:3), I-lipid
replicated O
(Supplementary O
Table O
2). O

Such O
effective O
mechanism O
might O
results O
in O
the O
activation O
and O
successful O
antioxidative O
response, O
as O
displayed O
by O
the O
decreased O
concentration O
of O
9-HODE, B-lipid
and O
9-oxoODE O
in O
centenarians. O

In O
this O
context O
malondialdehyde, O
4-hydroxynonenal, B-lipid
propanal B-lipid
and O
hexanal B-lipid
have O
been O
described O
as O
suitable O
markers O
[, O
]. O

Low O
and O
high O
energy O
spectra O
for O
coeluting O
TG B-lipid
(52:4) I-lipid
and O
TG B-lipid
(54:5) I-lipid
species, O
displaying O
neutral O
losses O
(NL) O
and O
fragments O
indicative O
of O
fatty O
acyl O
chains O
16:0, O
18:0, O
18:1, O
18:2, O
and O
18:3 O
acyl O
chains. O

To O
analyze O
15-HETE, B-lipid
20 O
HETE, O
11(12)-DiHET O
and O
14(15)-DiHET O
a O
modified O
version O
of O
the O
method O
described O
by O
Mangal O
et O
al. O
was O
used. O

Different O
lyso O
PCs O
in O
addition O
to O
oleamide O
and O
eicosatrienoic B-lipid
acid I-lipid
that O
were O
also O
found O
to O
be O
significant O
in O
our O
study O
have O
been O
previously O
included O
in O
a O
panel O
of O
biomarkers O
for O
differentiating O
early O
stage O
colorectal O
cancer O
patients O
from O
healthy O
controls O
that O
was O
shown O
to O
be O
more O
effective O
than O
the O
carcinoembryonic O
antigen O
biomarker O
usually O
utilised O
in O
diagnosis O
of O
the O
disease. O

A O
redirection O
of O
COX-2 O
metabolism O
toward O
15-HETE B-lipid
and O
its O
anti-inflammatory O
lipoxin O
derivates O
upon O
ASA O
treatment O
has O
been O
demonstrated O
in O
rat O
hepatocytes O
and O
human O
lung O
cancer O
cell O
lines. O

In O
the O
schizophrenia O
cohort, O
significant O
differences O
were O
apparent O
in O
several O
saturated O
FA, O
such O
as O
16:0 O
(palmitic O
acid), O
14:0 O
(myristic O
acid), O
24:0 O
(lignoceric O
acid), O
and O
the O
unsaturated O
essential O
FA B-lipid
18:2 I-lipid
(linoleic O
acid). O

The O
intra-run O
accuracy O
levels O
were O
−3.2–0.0%RE O
and O
−1.0–4.1%RE O
for O
Cer(22:0) B-lipid
and O
Cer(24:0), B-lipid
respectively. O

These O
OzID O
signals O
can O
thus O
be O
used O
to O
assign O
the O
structure O
of O
the O
sphingomyelin O
eluting O
at O
this O
time O
to O
SM O
d18:2(n O
-4)/22:0, O
while O
the O
other O
two O
contributors, O
SM B-lipid
d18:1/22:1 I-lipid
and O
SM B-lipid
d16:1/24:1, I-lipid
can O
be O
excluded O
from O
consideration O
(in O
this O
retention O
time O
slice) O
as O
no O
losses O
characteristic O
of O
the O
expected O
n O
-7 O
or O
n O
-9 O
sites O
of O
unsaturation O
in O
the O
associated O
side O
chains O
were O
observed. O

Identified O
metabolites: O
3, O
alanine; O
6, O
asparagine; O
7, O
aspartic O
acid; O
8, O
betaine; O
9, O
citric O
acid; O
12, O
formic O
acid; O
15, O
glutamic O
acid; O
17, O
glycine; O
20, O
histidine; O
21, O
3-hydroxybutyric O
acid; O
22, O
4-hydroxyproline; O
23, O
2-hydroxyisobutyric O
acid; O
25, O
isoleucine; O
28, O
lactic O
acid; O
31, O
maleic O
acid; O
33, O
malonic O
acid; O
39, O
propionic B-lipid
acid; I-lipid
48, O
valine. O

And O
then O
the O
12 O
annotated O
differential O
metabolites, O
which O
were O
cholesterol, O
linoleic O
acid, O
glycine, O
alanine, O
butanedioic B-lipid
acid, I-lipid
lactic O
acid, O
glucose, O
oleic O
acid, O
glucopyranose, O
sorbitol, O
proline O
and O
stearic O
acid, O
were O
explored O
by O
PLS-DA O
model O
classifying O
the O
non-ELS/MDD O
and O
healthy O
control. O

Non-esterified O
diols O
and O
alcohols O
of O
C18-PUFA O
LA O
and O
ALA O
in O
cluster O
1, O
represented O
by O
9-HODE, B-lipid
were O
enriched O
to O
a O
greater O
extent O
postprandially O
in O
pro-atherogenic O
TGRL. O

The O
raw O
LC-MS O
peak O
intensity O
ratio O
of O
PS(18:0_20:4) O
vs. O
3 O
other O
PS O
lipids O
[PS(18:0_18:1), O
PS(18:0_22:6), B-lipid
PS(18:0_20:4)] B-lipid
identified O
per O
donor O
sample. O

The O
inter-run O
accuracy O
was O
−1.6%RE O
and O
1.3%RE O
for O
Cer(22:0) B-lipid
and O
Cer(24:0), B-lipid
respectively. O

The O
LC-MS O
profiles O
demonstrated O
elevated O
levels O
of O
a O
limited O
number O
of O
polyunsaturated O
long O
chain O
PCs O
(PC(40:7), O
PC(40:6), B-lipid
PC(38:4)) B-lipid
and O
of O
SM(36:3), B-lipid
which O
has O
the O
longest O
chain O
and O
the O
highest O
unsaturation O
among O
all O
detected O
SMs. O

As O
shown O
in O
(Methanol O
precipitation) O
and O
1B O
(Methanol-ethanol O
precipitation), O
while O
most O
compounds O
were O
recovered O
and O
resolved O
using O
RPC, O
cholesterol O
and O
TG(17:2/17:2/18:0) B-lipid
were O
not O
seen O
when O
either O
precipitation O
method O
was O
used. O
also O
includes O
data O
resulting O
from O
MTBE O
extraction O
and O
MTBE:SPE O
extraction, O
as O
discussed O
in O
detail O
later. O

Lipidomic O
analysis O
also O
revealed O
changes O
in O
key O
membrane O
components, O
including O
a O
decrease O
in O
PC B-lipid
46:2. I-lipid

All O
definitions O
were O
obtained O
from O
the O
National O
Cholesterol B-lipid
Education O
Program's O
Adult O
Treatment O
Panel O
III O
report O
. O

We O
concluded O
that O
poor O
survival O
was O
due O
to O
the O
increase O
of O
PC(42:11) B-lipid
and O
with O
the O
decrease O
of O
LPE(22:0/0:0). B-lipid

Oxidative O
stress O
is O
the O
trigger O
for O
the O
production O
of O
fatty O
aldehydes, O
such O
as O
4-hydroxy-2-nonenal, B-lipid
in O
human O
metabolism. O

Measurements O
were O
performed O
in O
two O
subsets O
of O
the O
total O
study O
population O
in O
the O
Cholesterol B-lipid
and O
Pharmacogenetics O
(CAP) O
study: O
Full O
Range O
of O
Response O
(FR), O
and O
Good O
and O
Poor O
Responders O
(GPR) O
were O
100 O
individuals O
randomly O
selected O
from O
across O
the O
entire O
range O
of O
LDL-C O
responses O
in O
CAP. O

10-HdoHE, O
12-HEPE, B-lipid
and O
14-HDoHE B-lipid
are O
examples O
of O
potentially O
anti-inflammatory O
ω-3 O
fatty O
acids O
[, O
]. O

Using O
PC B-lipid
34:1 I-lipid
as O
an O
example, O
MS_2 O
CID O
of O
[M O
+ O
HCO_3 O
]_– O
(m O
/z O
820) O
suggested O
that O
it O
contained O
94% O
PC B-lipid
16:0/18:1 I-lipid
and O
6% O
PC B-lipid
18:1/16:0. I-lipid

For O
the O
extraction, O
methanol O
containing O
a O
mixture O
of O
internal O
standards O
(without O
CE B-lipid
(22:1)) I-lipid
was O
prepared, O
while O
MTBE O
containing O
cholesteryl O
ester O
(22:1) O
was O
used. O

Mediation O
analysis O
revealed O
that O
the O
lipids O
LysoPC(P-15:0), B-lipid
PC(P-34:4), B-lipid
and O
PC(38:6) B-lipid
may O
mediate O
the O
effects O
of O
ascites O
on O
recurrence. O

Furthermore, O
the O
12-LOX O
pathway O
metabolites O
like O
12-HETE, B-lipid
12-hydroxyeicosapentaenoic B-lipid
acid I-lipid
(12-HEPE), O
9-hydroxyoctadecanoic B-lipid
acid I-lipid
(9-HODE) O
and O
14-hydroxydocosahexaenoic B-lipid
acid I-lipid
(14-HDHA); O
the O
15-LOX O
metabolites O
15-HETE, B-lipid
13-HODE, B-lipid
15-HEPE B-lipid
and O
17-HDHA O
and O
various O
other O
PUFA O
metabolites O
like O
11-HETE, B-lipid
20-COOH-AA O
and O
the O
oxidative O
stress O
marker O
8iPGF_2 O
were O
all O
present O
at O
enhanced O
concentrations O
(significantly O
different) O
in O
AgP O
patient O
samples. O

The O
present O
study O
identified O
differences O
between O
subjects O
with O
RVD O
and O
those O
with O
either O
EH O
or O
normal O
blood O
pressure O
(control O
subjects) O
in O
terms O
of O
disparities O
between O
the O
2 O
groups O
in O
their O
plasma O
levels O
and O
urinary O
excretion O
of O
EETs O
and O
20-HETE B-lipid
and O
metabolism O
of O
EETs O
to O
DHETs. O

Elderly O
women O
had O
higher O
concentration O
of O
9-HODE B-lipid
and O
2,3-dinor-8-iso-PGF_2α O
than O
other O
groups O
(a O
and O
b). O

The O
fraction O
of O
heavy O
chains O
for O
PC B-lipid
34:1 I-lipid
is O
given O
by O
(0.55 O
+ O
2 O
× O
0.28) O
/ O
2 O
= O
0.55. O

Using O
PC B-lipid
18:1/16:0 I-lipid
as O
a O
model O
compound O
(10 O
μM, O
50/50, O
v/v, O
acetone/H_2 O
O O
with O
5 O
mM O
NH_4 O
HCO_3 O
), O
the O
solution O
was O
subjected O
to O
offline O
PB O
reaction O
and O
collected O
for O
nanoESI O
in O
negative O
ion O
mode O
(experimental O
details O
are O
provided O
in O
the O
ESI_† O
). O

Metabolites O
that O
contributed O
in O
both O
analyses O
were O
3,4-dihydroxybutanoic B-lipid
acid, I-lipid
docosapentaenoic B-lipid
acid, I-lipid
and O
uric O
acid. O

Low O
plasma O
levels O
of O
LysoPC(16:0) B-lipid
arose O
as O
a O
potential O
predictor O
of O
recurrence, O
especially O
in O
patients O
with O
early O
SR. O

Of O
these O
metabolites, O
2-Oxo-4-methylvaleric O
acid O
and O
4-Aminobutanoic B-lipid
acid I-lipid
showed O
the O
largest O
AUC O
values O
(AUC O
0.687 O
(95% O
CI: O
0.618–0.756), O
p O
< O
0.001; O
AUC O
0.687 O
(95% O
CI: O
0.618–0.756), O
p O
< O
0.001; O
respectively). O

For O
instance, O
in O
the O
molecular O
tandem O
mass O
spectral O
network, O
12-oxo O
LTB4 B-lipid
was O
clustered O
with O
spectra O
from O
four O
other O
unknown O
signals. O

Applying O
the O
same O
criteria O
used O
for O
the O
plasma O
lipidome O
to O
select O
the O
biomarker O
candidates, O
five O
lipids, O
LPC B-lipid
(16:1), I-lipid
PC B-lipid
(33:1), I-lipid
PC O
(35:4)B, O
PC O
(36:5)B O
and O
PC B-lipid
(36:6), I-lipid
discriminated O
meloxicam-treated O
from O
saline-treated O
cats. O

The O
EET O
pair O
displayed O
a O
slight O
difference O
in O
retention O
time O
(ΔRT=0.1) O
and O
the O
reported O
fragment O
ion O
m/z O
167 O
(red, O
) O
can O
be O
found O
in O
both O
8,9-EET B-lipid
and O
11,12-EET. B-lipid

The O
AUC O
values O
of O
MG B-lipid
(18:2), I-lipid
GNOE, O
PE B-lipid
(18:2) I-lipid
and O
ZS O
in O
the O
validation O
group O
were O
0.815, O
0.793, O
0.738 O
and O
0.930, O
respectively, O
which O
were O
all O
similar O
to O
their O
counterparts O
in O
the O
estimation O
group. O

Cholesterol B-lipid
was O
determined O
enzymatically O
using O
cholesterol O
esterase O
and O
cholesterol O
oxidase, O
intra-assay O
coefficient O
of O
variance O
(CV) O
was O
6 % O
and O
inter O
assay O
CV O
was O
3 %. O

Finally, O
we O
identified O
LysoPC(22:6) B-lipid
as O
a O
potential O
LAA O
biomarker. O

Of O
the O
differentially O
produced O
metabolites O
among O
the O
3 O
groups, O
24 O
metabolites O
(2-hydroxy-3-methylbutyric O
acid, O
3,4-dihydrxoybutyric O
acid, O
4-hydroxybutyric O
acid, O
6-aminocaproic O
acid, O
arabionse, O
arabitol, O
cellobiose, O
cytidine O
5′-diphosphocholine, O
ethanolamine, O
glyceraldehyde, O
GCDCA-3-sulfate, O
hydroxyprolyl-methionine, O
hypoxanthine, O
Ile-Thr, O
indole-3-acetamide, O
isoleucine, O
lactic O
acid, O
myo-inositol, O
pentanoic B-lipid
acid, I-lipid
threitol, O
threoninyl-methionine, O
trimethylamine O
N-oxide O
(TMAO), O
uridine, O
and O
valine) O
were O
consistently O
higher O
or O
lower. O

Elevated O
12-hydroxyeicosatetraenoic B-lipid
acid I-lipid
(12-HETE), O
15-HETE, B-lipid
sphingosine, O
γ-glutamyl O
oxidative O
stress-associated O
metabolites, O
xanthine, O
amino O
acids O
serine, O
glycine O
and O
aspartate, O
and O
a-cylcarnitines O
were O
strongly O
associated O
with O
the O
presence O
of O
HCC. O

Particularly, O
SM(18:1/24:0) B-lipid
was O
found O
to O
inversely O
correlate O
with O
MELD O
score, O
and O
positively O
correlate O
with O
inflammation O
grades O
in O
CHB O
patients; O
phytosphingosine O
and O
dihydrosphingosine O
were O
found O
to O
be O
decreased O
in O
the O
sera O
of O
HCC O
patients O
compared O
to O
cirrhosis O
patients. O

For O
example, O
recovery O
of O
PC(19:0/15:1) B-lipid
(p<0.001) O
increased O
by O
40%, O
and O
PE(20:3/18:1) B-lipid
(p=0.012) O
increased O
by O
58%. O

Ion O
mobilograms O
of O
the O
precursor O
and O
product O
ions O
obtained O
from O
negative O
ion O
CTS O
of O
(A) O
PC(17:0/20:4), B-lipid
(B) O
PE(17:0/20:4), B-lipid
(C) O
PA(17:0/20:4), B-lipid
(D) O
PS(17:0/20:4), B-lipid
(E) O
PI(17:0/20:4), B-lipid
and O
(F) O
SM(d18:1/18:0). B-lipid

The O
metabolites O
that O
had O
the O
largest O
difference O
were O
succinic O
acid, O
malate, O
and O
butanoic B-lipid
acid. I-lipid

Additionally, O
we O
observe O
an O
increased O
incorporation O
of O
long, O
odd O
chained O
FAs, O
such O
as O
FA B-lipid
17:0, I-lipid
17:1, O
15:0, O
and O
19:1, O
into O
lipid O
side O
chains, O
most O
likely O
because O
of O
the O
dairy-based O
premature O
infant O
diet. O

A. O
12-HETE, B-lipid
B. O
Taurine, O
C. O
Ceramide(d18:1/20:0), B-lipid
D. O
Sphingomyelin O
SM(d18:1/26:1 O
OH), O
E. O
Xanthosine, O
F. O
Plasmalogen O

It O
is O
worth O
noting O
that O
by O
using O
a O
much O
larger O
sampling O
size, O
i.e., O
70 O
plasma O
samples, O
previously O
Wang O
et O
al. O
discovered O
significant O
changes O
at O
subclass O
level O
for O
PE B-lipid
38:4 I-lipid
and O
PE B-lipid
38:6 I-lipid
in O
T2D O
plasma O
samples. O

Cholesterol B-lipid
levels O
changed O
very O
little. O

Palmitic B-lipid
acid I-lipid
(C16:0) O
is O
reported O
to O
induce O
lipoapoptosis O
in O
hepatocytes O
via O
mechanisms, O
including O
mitochondrial O
dysfunction O
and O
stress O
of O
endoplasmic O
reticulum. O

We O
highlight O
that O
none O
of O
the O
markers O
identified O
in O
this O
study O
have O
previously O
been O
related O
to O
CRC O
with O
the O
exception O
of O
LPC B-lipid
(18:1). I-lipid

Negative O
ion O
CTS O
analysis O
of O
phospholipid O
standards O
(PC, O
PE, O
PA, O
PS, O
and O
PI) O
containing O
heptadecanoic B-lipid
acid I-lipid
(17:0) O
esterified O
to O
the O
sn O
-1 O
position O
of O
the O
glycerol O
backbone O
and O
arachidonic O
acid O
(20:4) O
at O
the O
sn O
-2 O
position O
of O
the O
glycerol O
backbone O
and O
the O
sphingomyelin O
standard, O
SM(d18:1/18:0), B-lipid
was O
completed. O

The O
compositional O
changes O
of O
the O
C18:1 O
Δ9 O
and O
Δ11 O
isomers O
of O
PC B-lipid
15:0_18:1 I-lipid
were O
not O
statistically O
different O
between O
the O
normal O
and O
cancerous O
tissue O
samples. O

Interestingly, O
we O
demonstrated O
that O
most O
of O
the O
analysed O
tear O
metabolites, O
like O
PC B-lipid
34:1, I-lipid
PC B-lipid
36:2 I-lipid
and O
PC B-lipid
40:4, I-lipid
C0, O
C2, O
C3, O
Leu/Ile/Pro, O
Phe, O
Tyr, O
Glu, O
Met, O
and O
Lys/Gln O
were O
more O
retained O
in O
the O
first O
section O
of O
the O
imbibed O
paper O
strip. O

Interestingly, O
a O
significant O
decrease O
in O
LPC B-lipid
(18:1) I-lipid
was O
observed O
in O
non-advanced O
CRC O
patients O
but O
an O
increase O
in O
our O
patients O
with O
metastatic O
CRC, O
suggesting O
that O
this O
metabolite O
may O
potentially O
be O
useful O
as O
a O
biomarker O
of O
the O
progression O
of O
this O
disease. O

The O
zoomed-in O
region O
in O
shows O
two O
pairs O
of O
CC O
diagnostic O
ions O
(m O
/z O
171, O
197; O
m O
/z O
199, O
225) O
of O
C18:1, O
suggesting O
that O
PC B-lipid
18:1/16:0 I-lipid
contains O
two O
CC O
isomers, O
PC O
18:1(Δ9)/16:0 O
and O
PC O
18:1(Δ11)/16:0. O

We O
manually O
selected O
a O
combination O
of O
three O
metabolites O
namely O
pentadecanoic B-lipid
acid, I-lipid
1-linoleoylglycerophosphocholine O
and O
linoleoyl O
carnitine O
to O
create O
a O
biomarker O
model O
to O
distinguish O
between O
these O
two O
groups O
using O
RF O
(random O
forest) O
algorithm. O

Compared O
to O
elderly O
levels O
of O
eicosapentaenoic B-lipid
acid I-lipid
(EPA) O
decreased O
also O
in O
centenarians. O

, O
Our O
data O
clearly O
suggest O
that O
PC B-lipid
16:0_18:1 I-lipid
may O
contain O
four O
structural O
isomers O
from O
combinations O
of O
two O
sn O
-isomers O
and O
two O
CC O
location O
isomers O
of O
the O
C18:1. O

Moreover, O
serum O
levels O
of O
lysoPC(18:2), B-lipid
PhePhe, O
uridine, O
taurine, O
L-threonine, O
and O
(R)-3-Hydroxy-hexadecanoic B-lipid
acid I-lipid
were O
significantly O
correlated O
with O
disease O
activity O
scores O
(all O
p<0.05) O
in O
AOSD O
patients. O

(A) O
Receiver O
operating O
characteristic O
(ROC) O
plot O
obtained O
by O
combining O
three O
metabolites O
namely O
pentadecanoic B-lipid
acid, I-lipid
linoleoyl O
carnitine O
and O
1-linoleoylglycerophosphocholine. O

The O
RT O
and O
fragmentation O
pattern O
were O
virtually O
identical O
between O
marker O
and O
standard O
in O
the O
cases O
of O
sphinganine O
(Fig. ) O
and O
PC B-lipid
(18:1) I-lipid
(Fig. O

Due O
to O
all O
these O
neuroprotective O
properties, O
decreased O
plasma O
levels O
of O
LysoPC(16:0) B-lipid
could O
contribute O
to O
an O
early O
SR O
risk. O

Panel O
A, O
Concentrations O
(μmol/l) O
of O
lignoceric O
acid O
(FA(24:0)) O
and O
nervonic O
acid O
(FA(24:1)) O
in O
hepatocellular O
carcinoma O
(HCC; O
20 O
cases), O
acute O
myelogenous O
leukemia O
(AML; O
22 O
cases), O
liver O
cirrhosis O
(LC; O
7 O
cases) O
and O
healthy O
volunteers O
(HV; O
6 O
subjects). O

Moreover, O
lysoPC O
(22:6) O
and O
LPA B-lipid
(18:1) I-lipid
were O
revealed O
as O
independent O
factors O
for O
future O
LC O
incident O
via O
logistic O
regression O
analysis. O

Specifically, O
a O
combination O
profile O
of O
LysoPC O
18.2, O
L-Proline, O
Hexadecanoic B-lipid
acid, I-lipid
Octadecanoic B-lipid
acid, I-lipid
Phenylalanine O
and O
LysoPC O
16:1 O
showed O
close O
correlation O
for O
eight O
weight-losing O
samples O
(≥5% O
weight O
loss) O
and O
nine O
weight-stable O
samples O
(<5%weight O
loss) O
between O
predicted O
and O
actual O
weight O
change O
(r O
= O
0.976, O
p O
= O
0.0014). O

The O
only O
statistically O
significant O
PC O
lipid O
that O
increased O
in O
fatalities O
was O
PC(16:0/16:0) B-lipid
(P O
value O
0.003) O
( O
and O
). O

Furthermore, O
overexpression O
of O
an O
ω O
-hydroxylase O
isozyme, O
which O
increased O
the O
production O
of O
20-HETE B-lipid
in O
blood O
vessels, O
caused O
endothelial O
dysfunction. O

Another O
study, O
comprising O
of O
30,252 O
breast O
cancer O
patients, O
revealed O
that O
eicosapentaenoic B-lipid
acid I-lipid
and O
docosahexaenoic B-lipid
acid I-lipid
were O
significantly O
inversely O
associated O
with O
risk O
for O
breast O
cancer O
(HR: O
0.70, O
95% O
CI: O
0.54–0.90; O
HR: O
0.67, O
95% O
CI: O
0.52–0.87). O

Only O
a O
few O
correlations O
were O
found O
for O
PC B-lipid
28:1, I-lipid
PC B-lipid
30:2, I-lipid
PC B-lipid
40:1, I-lipid
PC B-lipid
42:6, I-lipid
GPCe O
38:6 O
and O
SM B-lipid
22:3 I-lipid
within O
the O
respective O
lipid O
classes. O

From O
65 O
differential O
lipids O
highlighted O
between O
responder O
(RP) O
vs O
not O
responder O
(NRP) O
patients, O
five O
lipids O
were O
validated O
to O
predict O
response O
at O
T0: O
SM(d18:2/18:1), B-lipid
LysoPC O
(16:0/0:0), O
LysoPC O
(15:1(9z)/0:0), O
Lyso O
PE B-lipid
(22:5/0:0) I-lipid
and O
m/z= O
842.90 O
corresponding O
to O
a O
PC O
containing O
2 O
fatty O
acids O
of O
40 O
carbons O
totally. O

(A) O
Unsaturated O
fatty O
acids O
(contain O
one O
or O
more O
C=C O
double O
bonds) O
are O
prone O
to O
lipid O
peroxidation, O
resulting O
in O
the O
formation O
of O
lipid O
aldehydes, O
acrolein O
(AL), O
malondialdehyde O
(MDA) O
and O
4-hydroxynonenal B-lipid
(HNE). O

Since O
docosahexaenoic B-lipid
acid I-lipid
was O
the O
only O
lipid O
that O
was O
found O
in O
this O
study O
the O
cause O
of O
its O
enrichment O
in O
incubations O
with O
alpha-PEP O
remains O
speculative. O

For O
example, O
PC38:6 B-lipid
has O
been O
associated O
with O
an O
increased O
risk O
of O
diabetes. O

Linoleic B-lipid
acid, I-lipid
a O
doubly O
unsaturated O
fatty O
acid O
and O
an O
omega-6 O
fatty O
acid, O
could O
improve O
the O
age-associated O
decline O
in O
cognition O
and O
neural O
function O
in O
rats O
due O
to O
the O
enhancement O
of O
protective O
signaling, O
the O
alterations O
in O
membrane O
microstructures, O
the O
decreases O
in O
inflammation, O
and O
the O
prevention O
of O
the O
accumulation O
of O
polyubiquitinated O
protein O
aggregates O
in O
critical O
regions O
of O
the O
brain. O

The O
earlier O
eluting O
isomer O
of O
PC(38:4) B-lipid
gave O
rise O
to O
the O
fragment O
ions O
504.3, O
528.3 O
and O
534.3, O
matching O
with O
the O
potential O
fragmentation O
pattern O
of O
PC(18:1/20:3). B-lipid

Adjusted O
OR O
(95% O
CI) O
of O
MI, O
IS, O
and O
ICH O
for O
Mean O
Particle O
Diameter, O
Cholesterol, B-lipid
Triglycerides, O
and O
Apolipoproteins O
as O
Measured O
by O
Nuclear O
Magnetic O
Resonance O
Spectroscopy O
Estimates O
are O
ORs O
per O
1-SD O
higher O
metabolic O
marker. O

By O
way O
of O
contrast, O
20-HETE, B-lipid
which O
inhibits O
Na_+ O
-K_+ O
-2Cl_− O
cotransporter O
activity O
in O
the O
TAL, O
will O
promote O
Na_+ O
reabsorption O
and O
elevate O
blood O
pressure O
when O
deficient, O
as O
in O
the O
Dahl O
salt-sensitive O
rat. O

They O
observed O
that O
a O
few O
lipids O
like O
LysoPC O
(16:0), O
LPA B-lipid
(16:0/0:0) I-lipid
and O
LPA B-lipid
(0:0/16:0) I-lipid
were O
aberrantly O
expressed O
in O
CTCL O
plasma O
in O
positive O
and O
negative O
modes. O

Conversion O
to O
AD O
(b.) O
preferentially O
channels O
putrescine O
towards O
the O
production O
of O
spermidines O
and O
spermines, O
whereas O
in O
stable O
MCI O
(a.) O
the O
fate O
of O
putrescine O
is O
the O
formation O
of O
N-acetylputrescine O
and O
4-aminobutanal. B-lipid

For O
the O
HETEs, O
compounds O
biosynthesized O
via O
the O
LOX O
pathway, O
a O
dramatic O
increase O
was O
visible, O
in O
particular O
for O
12-HETE B-lipid
and O
5-HETE B-lipid
(Fig. ). O

Arachidonic O
acid O
(C20:4) O
released O
by O
phospholipases O
from O
cell O
membrane O
is O
metabolized O
by O
lipoxygenases O
(LOX); O
especially, O
5-LOX O
generates O
5-HETE B-lipid
and O
leukotriene O
B_4 O
from O
arachidonic O
acid O
(C20:4). O

The O
transitions O
monitored O
were: O
337.2>207.1 O
and O
337.2>319.3 O
for O
14(15)-DiHET O
(rt: O
5.4 O
min), O
337.2>167.0 O
and O
337.2>319.3 O
for O
11(12)-DiHET O
(rt: O
5.7 O
min), O
319.2>275.3, O
319.2>301.3 O
and O
319.2>289.2 O
for O
20-HETE B-lipid
(rt: O
6.6 O
min), O
319.2>219.2, O
319.2>301.3 O
and O
319.2>175.0 O
for O
15-HETE B-lipid
(rt: O
7.6 O
min), O
319.2>179.2, O
319.2>301.3 O
and O
319.2>257.2 O
for O
12-HETE B-lipid
(rt: O
8.2 O
min), O
303.2>259.2, O
303.2>205.1 O
and O
303.2>58.7 O
for O
AA O
(rt: O
15.1 O
min) O
and O
311.3>267.3 O
for O
AA-d8 O
(rt: O
14.9 O
min). O

Of O
all O
the O
metabolites, O
we O
found O
that O
20-HETE B-lipid
had O
the O
highest O
fold-change. O

Glutamate, O
linoleic O
acid, O
and O
PC B-lipid
(16:0/0:0) I-lipid
were O
selected O
due O
to O
their O
high O
abundance O
and O
important O
roles O
in O
biochemistry. O

Among O
these O
4 O
metabolites, O
oral O
fat-specific O
correlation O
was O
seen O
only O
with O
LysoPC(16:0) B-lipid
and O
SM(d18:1/24:1) B-lipid
(i,k–n). O

Due O
to O
its O
chemotactic O
properties, O
12-HETE B-lipid
has O
been O
linked O
to O
healing O
processes O
during O
inflammation O
[, O
]. O

High O
concentrations O
of O
PGs, O
LTB4 B-lipid
and O
cysteinyl-leukotrienes O
have O
been O
reported O
to O
promote O
the O
accumulation O
of O
inflammatory O
cells O
such O
as O
polymorphonuclear O
leukocytes O
(PMNs) O
by O
increasing O
the O
blood O
flow O
and O
vascular O
permeability O
. O

For O
the O
metabolites, O
lysoPC(16:0), B-lipid
PC(P-16:0/20:4), B-lipid
linoleic O
acid, O
and O
linoleyl O
carnitine, O
the O
analytical O
variation O
values O
were O
less O
than O
half O
of O
the O
individual O
variation O
values O
(CVa O
< O
1/2 O
CVi) O
indicating O
adequate O
precision. O

Particularly, O
decreased O
LysoPG(20:5) B-lipid
level O
was O
identified O
as O
the O
most O
important O
prognostic O
feature O
in O
our O
model, O
which O
may O
provide O
additional O
prognostic O
information O
for O
EOC. O

Interestingly, O
the O
spectrum O
at O
m/z O
of O
855.6 O
corresponded O
to O
[M + Na]_+ O
ion O
of O
PI34:3. B-lipid

LTB4 B-lipid
was O
found O
to O
be O
significant O
owing O
to O
its O
apparent O
complete O
depletion O
in O
serum O
of O
CLL O
patients. O

To O
confirm O
their O
identity, O
two O
marker O
fatty O
acids, O
arachidonic O
acid O
and O
eicosatrienoic B-lipid
acid, I-lipid
were O
matched O
against O
the O
retention O
times O
of O
their O
corresponding O
standards O
on O
a O
C4 O
reversed O
phase O
column. O

However, O
there O
are O
several O
standards O
with O
S/N O
less O
than O
1500; O
heptanoic B-lipid
acid I-lipid
(S/N O
= O
18), O
decanoic B-lipid
acid I-lipid
(S/N O
= O
83), O
oxalic O
acid O
(S/N O
= O
47) O
and O
adipic O
acid O
(S/N O
= O
87). O

For O
example, O
positive O
correlations O
between O
LPI B-lipid
(16:0) I-lipid
with O
palmitic O
acid O
(16:0) O
and O
hexadecanoylcarnitine O
(C16) O
were O
observed. O

The O
overweight O
group O
showed O
significant O
decreases O
in O
11 O
metabolites—lysoPCs O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:2, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
and O
PC O
(18:0/20:4)—and O
significant O
increases O
in O
6 O
metabolites—L-leucine, O
palmitic O
amide, O
L-octanoylcarnitine, O
decanoylcarnitine, O
PC B-lipid
(18:2/18:2), I-lipid
and O
lactosylceramide. O

However, O
arachidonic O
acid O
(ARA, O
20:4) O
and O
docosahexaenoic B-lipid
acid I-lipid
(DHA O
22:6), O
which O
are O
long-chain O
polyunsaturated O
acids O
(PUFAs), O
were O
decreased O
in O
R_AT O
and O
R_BT O
, O
respectively O
(Shown O
in O
Figures O
, O
). O

In O
this O
study O
as O
well, O
a O
comparison O
between O
the O
OSCC O
and O
OD O
before O
surgery O
revealed O
a O
significant O
increase O
in O
nonanoic B-lipid
acid I-lipid
in O
the O
OSCC O
group, O
consistent O
with O
Scachez O
et O
al., O
who O
investigated O
lung O
cancer. O

report O
concentrations O
after O
consumption O
of O
JWH-018 O
and O
JWH-073, O
which O
were O
in O
the O
low O
nanogram O
per O
milliliter O
range O
for O
the O
main O
metabolites O
(JWH-018 O
5-hydroxypentyl O
23 O
ng/mL/26 O
ng/mL; O
JWH-018 O
pentanoic B-lipid
acid I-lipid
16.5 O
ng/mL/16 O
ng/mL, O
JWH-073 O
butanoic B-lipid
acid I-lipid
6.2 O
ng/mL). O

The O
diagnostic O
utility O
in O
combining O
measurement O
of O
the O
up-regulated O
(decanoylcarnitine, O
lysoPC(16:0), B-lipid
lysoPC(18:0), B-lipid
lysoPC(16:1) B-lipid
and O
octanoylcarnitine) O
with O
the O
down-regulated O
(linoleic O
acid O
and O
uric O
acid) O
was O
relatively O
high, O
with O
a O
sensitivity O
and O
specificity O
up O
to O
90.2% O
and O
96.0%, O
respectively. O

In O
addition, O
three O
downregulated O
LPCs, O
LPC(14:0), B-lipid
LPC(20:3), B-lipid
and O
LPC(22:6), B-lipid
were O
found O
for O
this O
comparison O
of O
patient O
classes O
by O
random O
forests. O

The O
methanol O
used O
for O
extraction O
was O
spiked O
with O
the O
following O
compounds, O
chosen O
to O
encompass O
most O
of O
the O
retention O
time-m/z O
space O
covered O
by O
the O
method, O
while O
being O
undetected O
in O
nonspiked O
human O
serum O
extracts: O
tryptophan-d_5 O
(indole-d_5 O
), O
PC(13:0/0:0), B-lipid
NEFA(19:0), O
and O
dehydrocholic O
acid. O

Similarly, O
cholesterol, O
Cer(d18:0/24:1) B-lipid
(p<0.001), O
TG(17:2/17:2/18:2) B-lipid
(p=0.00261), O
and O
TG(17:2/17:2/18:0) B-lipid
(p=0.00291) O
were O
detected O
when O
MTBE O
was O
used O
but O
were O
not O
observed O
when O
methanol O
alone O
was O
used. O

PA B-lipid
(38:4) I-lipid
was O
the O
only O
species O
identified O
in O
virions, O
and O
it O
was O
also O
elevated O
in O
infected O
relative O
to O
mock-infected O
cells. O

For O
instance, O
the O
peak O
at O
m/z O
718.6 O
in O
141 Da O
NLS O
(monoisotopic O
molecular O
mass: O
717.6 Da, O
RT: O
5.2 min) O
was O
identified O
as O
PE B-lipid
16:0_18:1, I-lipid
based O
on O
the O
detection O
of O
fatty O
acyl O
anions O
at O
m/z O
255 O
(C16:0) O
and O
m/z O
281 O
(C18:1) O
(Supplementary O
Fig. O

The O
results O
are O
listed O
in O
, O
where O
AFMK O
and O
sphinganine O
demonstrated O
relatively O
high O
sensitivity O
(≥80%), O
and O
inosine, O
indoleacetic O
acid O
and O
PS(O-18:0/0:0) B-lipid
yielded O
specificity O
of O
more O
than O
80%. O

Compared O
with O
HCs, O
DN-MDD O
exhibited O
a O
decrease O
in O
fatty O
acids, O
including; O
capric O
acid, O
cis-9-palmitoleic O
acid, O
dodecanoic B-lipid
acid, I-lipid
oleic O
acid O
and O
palmitic O
acid, O
and O
the O
polyunsaturated O
fatty O
acids O
(PUFAs), O
including; O
eicosapentaenoic B-lipid
acid I-lipid
(EPA,ω-3) O
and O
arachidonic O
acid O
(AA,ω-6) O
which O
is O
generated O
from O
phospholipids O
through O
phospholipase O
A2 O
with O
lysophospholipids O
as O
a O
by-product. O

A O
total O
of O
2 O
volatile O
metabolites O
(2-methylbutanal O
and O
decanoic O
acid) O
were O
able O
to O
distinguish O
the O
patients O
with O
CD20_− O
B-NHL O
and O
CD20_+ O
B-NHL O
with O
significantly O
higher O
concentration O
levels O
in O
patients O
with O
CD20_− O
B-NHL. O

These O
are O
palmitic O
acid, O
stearic O
acid, O
oleic O
acid, O
benzoic O
acid, O
butanoic B-lipid
acid, I-lipid
cholesterol, O
glycine, O
3-heptanone, O
4-heptanone, O
hexanal, B-lipid
1-tetradecanol O
and O
naphthalene O
. O

Among O
the O
20 O
candidate O
lipid O
markers, O
decreasing O
levels O
were O
observed O
in O
18 O
lipid O
species O
in O
SqCC O
patients; O
however, O
2 O
lipid O
species, O
PC(38:6) B-lipid
and O
PI(38:4), B-lipid
presented O
an O
increased O
level O
in O
SqCC O
plasma O
when O
compared O
with O
the O
controls. O

Equally O
good O
matching O
was O
observed O
for O
retention O
times O
of O
authentic O
standard O
of O
SM B-lipid
(36:2) I-lipid
and O
the O
observed O
SM B-lipid
(36:2) I-lipid
(not O
shown). O

Abbreviations: O
MSA: O
multiple O
system O
atrophy; O
PSP: O
progressive O
supranuclear O
palsy; O
AUC: O
area O
under O
the O
curve; O
FA: O
fatty O
acid; O
LysoPC(16:0): B-lipid
lysophosphatidylcholine O
(16:0); O
DHEAS: O
dehydroisoandrosterone O
3-sulfate; O
SDMA: O
symmetric O
dimethylarginine O
fatty O
acid; O
AC: O
acylcarnitine; O
Met: O
methionine. O

MS/MS O
fragmentation O
of O
PC(40:7) B-lipid
lead O
to O
its O
identification O
as O
PC(18:1/22:6) B-lipid
based O
on O
the O
fragment O
ions O
550.3 O
([M+Li-R1′CHCO]+) O
and O
556.3 O
([M+Li-R1CO2Li]+). O

This O
finding O
is O
aligned O
with O
earlier O
studies O
that O
illuminated O
salutary O
effects O
of O
longer O
unsaturated O
FFAs, O
such O
as O
oleate O
and O
eicosapentaenoic B-lipid
acid, I-lipid
on O
inflammation, O
endoplasmic O
reticulum O
stress, O
and O
eventually O
better O
podocyte O
and O
pancreatic O
cell O
survival O
compared O
with O
the O
effect O
of O
saturated O
FFA O
palmitate O
(–). O

Particularly, O
two O
of O
the O
three O
candidate O
metabolites O
that O
we O
identified O
as O
having O
the O
best O
predicting O
power, O
PE B-lipid
(18:2) I-lipid
and O
glycerophospho-N-ethanolamine, O
belonged O
to O
this O
category. O

The O
meta-analysis O
provided O
some O
evidence O
for O
the O
involvement O
of O
ω O
-3 O
fatty O
acids O
(including O
docosahexaenoic B-lipid
acid I-lipid
and O
high-density O
lipoproteins). O

By O
UPLC-MS, O
we O
identified O
2 O
metabolites O
(with O
an O
LoA O
≤ O
3) O
that O
were O
higher O
in O
PRP O
compared O
with O
PFP O
samples: O
PE(18:0/18:2) B-lipid
and O
PC(P-16:0/20:4). B-lipid

Excellent O
recoveries O
of O
Cer(22:0) B-lipid
and O
Cer(24:0) B-lipid
from O
plasma O
and O
from O
BSA O
were O
obtained O
(see O
). O

Chromatograms O
from O
quality O
control O
samples O
(QCs) O
at O
pH O
7 O
and O
pH O
2 O
(1: O
3-methylbut-3-en-2-ol; O
2: O
1,4-xylene; O
3: O
2,7-dimethyloctan-1-ol; O
4: O
2-(4-methylcyclohex-3-en-1-yl)propan2-ol O
; O
5: O
3,7-dimethyloct-7-en-1-ol; O
6: O
1,3-benzothiazol; O
7: O
decan-1-ol; O
8: O
pentadecan-2-one; O
9: O
cyclohexanone; O
10: O
4-methyheptan-2-one; O
11: O
2-methylpentan-1,3-diol; O
12: O
4-methylbenzaldehyde; O
13: O
methyl O
benzoate; O
14: O
nonanoic B-lipid
acid; I-lipid
15: O
decanoic O
acid). O

Serum O
alanine O
aminotransferase O
(ALT), O
aspartate O
aminotransferase O
(AST), O
gamma-glutamyl O
transferase O
(GT), O
glucose, O
cholesterol, O
and O
triglyceride O
concentrations O
were O
measured O
with O
ALT, O
AST, O
GT, O
Glucose, O
Cholesterol, B-lipid
and O
Triglycerides O
System O
Reagent, O
(Beckman O
Coulter O
Biomedical). O

For O
example, O
signal O
intensity O
drops O
between O
the O
first O
and O
the O
sixth O
exhalation O
for O
4-hydroxy-2-nonenal B-lipid
is O
around O
50%, O
for O
2-dodecenal O
the O
drop O
is O
around O
30%, O
whereas O
for O
4-hydroxy-2,6-pentadecadienal B-lipid
signal O
intensity O
remains O
stable O
(or O
even O
increases O
after O
the O
first O
exhalation). O

oxoODE O
(21.9% O
in O
PMC), O
13-HOTrE O
(25.5% O
in O
plasma), O
and O
20-HETE B-lipid
(21.8% O
in O
PMC) O
at O
the O
lowest O
QC1level. O

It O
is O
observed O
that O
pyridoxine O
levels O
are O
lowered O
in O
the O
stages O
of O
II, O
III, O
and O
IV O
as O
compared O
to O
stage O
0 O
and O
I. O
Cholesterol, B-lipid
taurocholic O
acid, O
and O
deoxycholic O
acid O
are O
three O
related O
metabolites O
participating O
in O
bile O
acid O
biosynthesis O
whose O
levels O
had O
increased O
in O
the O
II O
and O
III O
stage O
groups. O

Adult O
PKU, O
Treatment, O
Cholesterol, B-lipid
Lipoprotein O
subclasses, O
NMR O

A O
receiver O
operator O
curve O
analysis O
revealed O
that O
the O
combination O
of O
4-hydroxypentenoic B-lipid
acid, I-lipid
arabinose, O
glycochenodeoxycholate-3-sulfate, O
isoleucine, O
serine, O
and O
xanthine O
produced O
a O
moderate O
diagnostic O
score O
with O
a O
sensitivity O
(specificity) O
of O
75% O
(78%) O
for O
distinguishing O
OSA O
from O
those O
without O
OSA. O

The O
ions O
at O
m/z O
687, O
715, O
743, O
771, O
and O
797 O
were O
identified O
as O
SM(d18:1/16:0), B-lipid
SM(d18:1/18:0), B-lipid
SM(d18:1/20:0), B-lipid
SM(d18:1/22:0), B-lipid
and O
SM(d18:1/24:1), B-lipid
respectively. O

In O
brief, O
urine O
sample O
preparation O
consisted O
of O
1) O
pre-extraction O
on O
a O
Sep-Pak O
C18 O
column O
with O
the O
recovery O
standard O
medroxyprogesterone, O
2) O
enzymatic O
hydrolysis O
with O
sulfatase O
and O
β-glucuronidase/arylsulfatase, O
3) O
extraction O
of O
the O
free O
steroids O
from O
the O
hydrolysis O
mixture O
again O
on O
a O
Sep-Pak O
C18 O
cartridge, O
4) O
derivatization O
with O
methoxyamine O
HCl O
2% O
in O
pyridine O
at O
60°C O
for O
one O
hour O
after O
adding O
the O
two O
standards O
Stigmasterol B-lipid
and O
3β5β-TH-aldosterone O
and O
derivatization O
with O
Trimethylsilylimidazole O
(TMSI) O
at O
100°C O
for O
16 O
hours, O
5) O
purification O
by O
gel O
filtration O
on O
a O
Lipidex O
5000 O
column. O

Besides O
the O
well-described O
AA O
metabolites, O
oxylipins O
derived O
from O
linoleic O
acid, O
dihomo-γ-linolenic O
acid, O
α-linolenic O
acid, O
eicosapentaenoic B-lipid
acid I-lipid
and O
docosahexaenoic B-lipid
acid I-lipid
were O
included. O

The O
results O
demonstrated O
that O
the O
phosphatidic O
acid O
and O
CE B-lipid
(18:0) I-lipid
levels O
in O
HU O
were O
lower O
than O
those O
in O
HU+NAFLD; O
by O
contrast, O
the O
inosine O
levels O
in O
HU O
were O
higher O
than O
those O
in O
HU+NAFLD. O

Based O
on O
this O
pattern, O
a O
higher O
LPC B-lipid
16:1 I-lipid
level O
was O
detected O
in O
the O
obese O
group, O
while O
higher O
levels O
of O
other O
LPC O
species O
were O
observed O
in O
nonobese O
subjects. O

Samples O
were O
extracted O
by O
adding O
100 O
µL O
of O
serum O
to O
1 O
mL O
of O
ice-cold O
extraction O
solvent O
consisting O
of O
methanol/chloroform O
(v:v O
= O
3:1) O
containing O
10 O
µg/mL O
heptadecanoic B-lipid
acid I-lipid
and O
10 O
µg/mL O
norleucine O
as O
internal O
standards. O

Interestingly, O
PC B-lipid
(34:2), I-lipid
PC B-lipid
(34:1), I-lipid
PC B-lipid
(36:3), I-lipid
and O
PC B-lipid
(36:2) I-lipid
increased O
in O
both O
tissues O
and O
sera O
of O
MF O
patients, O
whereas O
SM B-lipid
(16:0), I-lipid
PC B-lipid
(32:0), I-lipid
and O
PC B-lipid
(38:4) I-lipid
levels O
increased O
in O
the O
sera O
but O
decreased O
in O
the O
tissues O
of O
MF O
patients O
compared O
to O
control O
subjects. O

Norepinephrine O
(d_6 O
), O
cholic O
acid O
(d_4 O
), O
epinephrine O
(d_3 O
), O
dopamine O
(d_4 O
), O
melatonin O
(d_4 O
), O
4-aminobutanoic B-lipid
acid I-lipid
(d_6 O
) O
and O
phenylalanine O
(d_5 O
) O
were O
obtained O
from O
CDN O
Isotopes O
(Point-Claire, O
QC, O
Canada), O
while O
_13 O
C_6 O
- O
thyroxine O
was O
purchased O
from O
Toronto O
Research O
Chemicals O
(Toronto, O
ON, O
Canada). O

In O
particular, O
FA B-lipid
(20:4), I-lipid
or O
arachidonic O
acid, O
is O
a O
precursor O
of O
prostaglandins O
that O
were O
shown O
to O
be O
elevated O
in O
BCC O
compared O
with O
normal O
skin, O
and O
are O
predictive O
of O
tumor O
aggressiveness O
(, O
). O

The O
exclusive O
increase O
of O
PC(16:0/16:0) B-lipid
supports O
fatty O
liver O
disease O
with O
EVD, O
as O
PC(32:0) B-lipid
was O
recently O
reported O
as O
a O
potential O
signature O
of O
progressive O
forms O
of O
fatty O
liver O
disease. O

The O
differentiated O
metabolites O
identified O
in O
the O
CD O
samples O
included O
tyrosine, O
an O
ornithine O
isomer, O
arachidonic O
acid, O
eicosatrienoic B-lipid
acid, I-lipid
docosatetraenoic B-lipid
acid, I-lipid
a O
sphingomyelin, O
a O
ceramide, O
and O
dimethylsphinganine. O

The O
linoleate O
metabolites O
13-HODE B-lipid
+ O
9-HODE B-lipid
were O
also O
significantly O
higher O
in O
C-3N O
subjects. O

Stability O
of O
the O
Cer(22:0) B-lipid
and O
Cer(24:0) B-lipid
in O
the O
human O
plasma O
was O
evaluated O
under O
a O
variety O
of O
conditions O
to O
establish O
length O
of O
storage O
and O
sample O
processing O
conditions O
(see O
). O

Although O
ions O
at O
m O
/z O
445 O
and O
m O
/z O
419 O
were O
each O
detected O
at O
low O
abundances O
in O
CID O
of O
PC B-lipid
16:0/18:1 I-lipid
and O
PC B-lipid
18:1/16:0, I-lipid
they O
were O
later O
proved O
to O
be O
the O
“sn O
-1 O
fragments” O
resulting O
from O
corresponding O
sn O
-isomers, O
which O
are O
present O
as O
minor O
impurities O
in O
the O
supplied O
samples. O

Hexadecanoic B-lipid
acid. I-lipid

 , O
compared O
with O
the O
corresponding O
levels O
in O
HC, O
the O
levels O
of O
saturated O
and O
monounsaturated O
PCs O
such O
as O
PC(15:0/18:1), B-lipid
PC(18:0/16:0) B-lipid
and O
PC(18:0/20:1) B-lipid
were O
significantly O
increased, O
whereas O
the O
levels O
of O
polyunsaturated O
PCs O
such O
as O
PC(17:2/2:0), B-lipid
PC(18:4/3:0), B-lipid
PC(15:0/18:2), B-lipid
PC(16:0/18:3), B-lipid
PC(17:0/18:2), B-lipid
PC(18:2/18:2), B-lipid
PC(16:0/20:3), B-lipid
PC(15:0/22:6) B-lipid
and O
PC(24:4/17:2) B-lipid
significantly O
decreased O
in O
early-stage O
NSCLC O
patients. O

shows O
down-regulation O
of O
fatty O
acid O
of O
tetracosahexaenoic O
acid O
and O
3-hydroxy-eicosanoic B-lipid
acid I-lipid
in O
HCC O
cases O
compared O
to O
cirrhotic O
controls. O

4-hydroxy-2-dodecenal B-lipid
shows O
a O
deviating O
pattern O
that O
may O
be O
caused O
by O
an O
interfering O
peak. O

Stability O
of O
5,6-EET B-lipid
and O
deuterated O
5,6-EET-d_11 O
decreased O
to O
61 O
and O
57%, O
respectively, O
at O
this O
storage O
condition O
for O
plasma O
extract O
at O
24 O
h O
relative O
to O
0 O
h. O

In O
this O
model, O
myo-inositol O
and O
hexadecenoic B-lipid
acid I-lipid
were O
associated O
with O
long O
survival O
time. O

LPA(16:0) B-lipid
was O
profiled O
by O
modification O
of O
a O
previously O
described O
method. O

Lactobacilli O
produce O
lactic O
acid O
and O
acetic O
acid O
from O
glucose O
and O
fructose O
by O
a O
fermentation O
process O
, O
while O
Veillonella O
transform O
lactic O
acid O
into O
acetic O
acid O
and O
propionic B-lipid
acid I-lipid
. O

Regarding O
correlation O
analysis, O
20-HETE B-lipid
circulating O
levels O
correlated O
positively O
with O
BMI O
and O
diastolic O
blood O
pressure O
(r O
= O
0.427, O
p O
= O
0.007; O
r O
= O
0.365, O
p O
= O
0.028; O
respectively, O
) O
in O
the O
population O
studied. O

Linoleic B-lipid
acid I-lipid
has O
been O
shown O
recently O
to O
inhibit O
the O
growth O
of O
CRC O
cells O
by O
mediating O
oxidative O
stress O
and O
mitochondrial O
dysfunction. O

There O
is O
no O
obvious O
trend O
in O
the O
changes O
of O
the O
Δ9/Δ11 O
isomers O
and O
neither O
do O
the O
changes O
correlate O
with O
relative O
isomeric O
composition O
in O
free O
FA B-lipid
18:1 I-lipid
(I O
_Δ9 O
/I O
_Δ11 O
 = 10.5 ± O

Chief O
among O
them O
are O
several O
GPLs O
that O
are O
believed O
to O
have O
biological O
significance O
in O
cancer O
physiology, O
including O
PC(32:1), B-lipid
PC(34:1), B-lipid
PS(38:5), B-lipid
PE(38:6), B-lipid
PC(32:3), B-lipid
and O
PC(34:2)._5 O
, O

Platelets, O
common O
sources O
of O
MVs, O
have O
been O
shown O
to O
externalize O
PS(18:0_18:1) B-lipid
and O
PS(18:0_20:4) B-lipid
from O
the O
inner O
to O
outer O
membrane O
when O
activated O
by O
thrombin. O

In O
contrast, O
ceramide O
(Cer) O
Cer(d18:1/21:0) B-lipid
and O
Cer(d18:2/23:0), B-lipid
ursodeoxycholic O
acid O
(UDCA), O
and O
the O
ratios O
BCAA O
to O
ArAA, O
and O
BCAA O
to O
tyrosine O
(BTR) O
decreased O
along O
with O
the O
fibrosis O
stages O
of O
the O
studied O
patients O
(absolute O
PCC > 0.98). O

In O
a O
second O
example O
from O
human O
plasma O
extract, O
the O
elution O
profile O
of O
a O
phosphatidylcholine O
of O
sum O
composition O
PC B-lipid
32:2 I-lipid
is O
shown O
in O
. O

LPC O
profiling O
revealed O
statistically O
significant O
downregulation O
of O
LPC(16:0) B-lipid
in O
HCC O
relative O
to O
AML O
(P<0.001) O
and O
HV O
(P<0.05). O

While O
the O
sensitivity O
for O
glucose, O
galactose, O
and O
cysteine O
+ O
cystine O
was O
≥85%, O
that O
for O
nonanoic B-lipid
acid I-lipid
was O
79%. O

The O
ABCD2 O
+ O
LAA O
+ O
LysoPC(20:4) B-lipid
model O
showed O
the O
highest O
calibration O
(χ_2 O
3.58, O
p O
= O
0.309), O
whereas O
the O
ABCD2 O
+ O
LAA O
+ O
LysoPC(16:0) B-lipid
model O
showed O
the O
lowest O
calibration O
values O
(χ_2 O
17.33, O
p O